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To my Family    
 
 
 
 
 
A human being should be able to change a diaper, plan an invasion, 
butcher a hog, conn a ship, design a building, write a sonnet, 
balance accounts, build a wall, set a bone, comfort the dying, take 
orders, give orders, cooperate, act alone, solve equations, analyze a 
new problem, pitch manure, program a computer, cook a tasty 
meal, fight efficiently, die gallantly. Specialization is for insects. 
 
 
- Robert A. Heinlein 
 
  
6 
 
 
 
 
Supervisors 
 
 
Docent Eero Pesonen 
Department of Anesthesiology and  
Intensive Care Medicine 
Helsinki University Hospital 
University of Helsinki 
Helsinki, Finland 
 
Professor Leena Lindgren 
Department of Anesthesiology and  
Intensive Care Medicine 
Tampere University Central Hospital 
University of Tampere 
Tampere, Finland 
 
 
 
 
Reviewers 
 
 
Professor Heikki Saha 
Department of Internal Medicine 
Tampere University Central Hospital 
Tampere, Finland 
 
Professor Mika Rämet 
Department of Pediatrics 
Oulu University Central Hospital 
Oulu, Finland
 
 
 
Opponent 
 
Professor Hannu Jalanko 
Department of Pediatrics 
Helsinki University Hospital 
Helsinki, Finland 
 
 
 
 
  
  
7 
 
ABSTRACT 
 
Renal transplantation represents the treatment of choice for the majority of patients with 
end-stage renal disease. Since the introduction of calcineurin inhibitor immunosuppressive 
drugs in the 1980s, we have witnessed a successful era for all solid organ transplantations. 
However, many kidneys continue to fail resulting from chronic allograft nephropathy years 
after transplantation. Increasing evidence from the last three decades suggests that early 
graft injury also jeopardizes long-term outcomes. As demand for renal transplants continues 
to rise, a better understanding of early allograft injury is required in order to develop 
protective interventions. 
 
This thesis focuses on the inflammatory mechanisms of early kidney graft injury as well as the 
differences in systemic inflammatory responses in patients following various 
immunosuppressive protocols. In total, 45 adult patients undergoing renal transplantation at 
Helsinki University Hospital were studied. Patients were recruited as a subset from a larger 
randomized study comparing three immunosuppressive protocols. Thus, 15 (group A), 14 
(group B), and 16 (group C) patients were consecutively recruited retaining the original 
randomization. In group A, patients received perioperative a 9-mg/kg infusion of 
antithymocyte globulin complemented by a triple immunosuppression therapy consisting of 
reduced dose cyclosporine, azathioprine, and steroids. Group B patients received two doses of 
the interleukin 2 (IL-2) receptor antagonist basiliximab with a reduced dose cyclosporine triple 
therapy as in group A. Group C patients received a conventional triple immunosuppression 
therapy of 10-mg/kg cyclosporine, azathioprine, and steroids. 
  
Central vein blood samples were taken before surgery, before graft reperfusion, and during 
reperfusion. In addition, during reperfusion blood samples were also obtained directly from 
the renal graft artery and vein in order to study phenomena local to the graft vascular bed. 
From blood samples, various established biomarkers of inflammation and coagulation were 
determined complemented with measurements of the graft blood flow.  
  
The primary findings from this study consisted of the associations between the investigated 
inflammatory markers and the pathways with ensuing delayed graft function (DGF). Marked 
neutrophil sequestration in the renal graft was demonstrated immediately after reinstitution 
of the blood flow. Later, this was associated with a diminishing blood flow. Antithymocyte 
globulin (ATG) administration provided an unforeseen but unique opportunity to observe 
graft reflow under a systemic pro-inflammatory state. In this situation, avid graft uptake of 
APC was noted. Thus, this uptake may prove protective. Therefore, as a pharmaceutical 
preparation already exists, albeit for a different indication, new therapeutic interventions in 
the context of transplantation could be explored in the future.   
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ABSTRACT IN FINNISH 
 
Valtaosalle loppuvaiheeseen edennyttä munuaistautia sairastavista potilaista paras 
hoitovaihtoehto on munuaisensiirto. Kuusikymmentäluvun kokeellisesta hoitomuodosta on 
kehittynyt nykypäivään tultaessa vakiintunutta toimintaa. Syklosporiini-lääke otettiin käyttöön 
neljä vuosikymmentä sitten, minkä jälkeen olemme saaneet todistaa elinsiirtojen 
voittokulkua. Edelleen kuitenkin vaikea ongelma on siirtomunuaiseen kehittyvä krooninen 
hyljintä, jonka vuoksi vuosien mittaan merkittävä määrä siirteistä menetetään. Noin kolmen 
vuosikymmenen tutkimusaineisto osoittaa, että siirteen varhaiset vauriot altistavat siirteen 
toiminnan heikkenemiselle ja siirteen menetykselle myös pitkällä aikavälillä. Koska siirtoa 
odottavia potilaita on jatkuvasti enemmän kuin tarjolla olevia siirteitä, parempi 
varhaisvaiheen vaurioiden ymmärtäminen olisi tärkeää suojaavien hoitojen ja toimenpiteiden 
kehittämiseksi. 
  
Tämä väitöskirjatutkimus keskittyy siirtomunuaista varhaisvaiheessa vaurioittavan 
tulehdusreaktion mekanismeihin, sekä eri hylkimisenestolääkityksiä käyttävien potilasryhmien 
tulehdusvasteiden eroihin. Tutkimukseemme osallistui neljäkymmentäviisi aikuista, joille 
tehtiin munaisensiirto Helsingin yliopistollisessa keskussairaalassa. Potilaat rekrytoitiin osana 
tutkimusta, jossa vertailtiin kolmea erilaista hylkimisenestolääkitysohjelmaa. Potilasrekrytointi 
suoritettiin peräkkäin kustakin hylkimisenestolääkityksen ryhmästä säilyttäen alkuperäinen 
ryhmien satunnaistaminen.  Ryhmässä A (15 potilasta) käytettiin leikkauksenaikaista 9mg/kg 
ATG infuusiota, alkuvaiheen matalaa syklosporiini-annostusta, atsatiopriinia ja 
kortikosteroideja. Ryhmässä B (14 potilasta) potilaat saivat kaksi infuusiota IL-2 -reseptorin 
estäjää basiliximabia ja muuten samanlaista, alkuvaiheessa matala-annoksista syklosporiini-
kolmoishoitoa kuten ryhmän A potilaatkin. Ryhmän C potilaat (16 potilasta) saivat 
traditionaalista kolmoishoitoa 10mg/kg syklosporiini-annostuksella, atsatiopriinilla ja 
kortikosteroideilla. 
  
Verinäytteet otettiin keskuslaskimosta ennen leikkausta, ennen siirteen reperfuusiota ja 
reperfuusion aikana. Tämän lisäksi reperfuusion aikana otettiin verinäytteet siirteen 
valtimosta ja laskimosta siirteen paikallisten ilmiöiden tarkastelemiseksi. Verinäytteistä 
määritettiin verenkuva sekä neutrofiilien ja monosyyttien CD11b ja L-selektiini –ekspressiot 
virtaussytometrialla. Edelleen plasmasta määritettiin laktoferriini-, tPA-, D-dimeeri-, 
protrombiinifragmentti 1 + 2 (F1+2), PAI-1, MMP9- ja TIMP-1 –pitoisuudet entsyymi-
immunologisesti (ELISA). Proteiini-C ja aktivoitu proteiini-C määritettiin entsyymi-kaappaus –
metodilla. Verenvirtaus siirteessä mitattiin pulssi-doppler virtausmittarilla. 
  
Tutkimuksen keskeisimmät tulokset koskevat tutkittujen markkerien assosiaatioita 
viivästyneeseen siirteen käynnistymiseen. Välittömästi verenkierron aukaisuun liittyen 
todettiin huomattava neutrofiilisolujen kertyminen siirteeseen. Tähän puolestaan liittyi 
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viiveellä siirteen verenkierron heikentyminen. ATG-annostelu aiheutti ennalta-
arvaamattoman proinflammatorisen reaktion, mikä tarjosi kiinnostavan mahdollisuuden 
tutkia munuaissiirteen verenkierron käynnistymistä systeemisen tulehdustilan vallitessa. 
Tutkimuksessamme totesimme ATG-ryhmässä siirteen kuluttavan runsaasti kiertävää 
aktivoitunutta proteiini-C:tä. On mahdollista, että aktivoituneen proteiini-C:n vaikutus voi 
tässä tilanteessa olla suojaava, mikä tarjoaa mahdollisuuden tulevaisuudessa 
lääkehoitotutkimuksiin. 
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INTRODUCTION 
 
Since the clinical introduction of calcineurin inhibitors in 1983, solid organ transplantation has 
become a highly successful treatment modality for various organ failure states. During this 
“calcineurin inhibitor era”, a dramatic increase in our understanding of human immunology 
accompanied by an increase in the absolute number of clinical transplantations performed 
worldwide occurred. Simultaneously, it has become painfully apparent that a further rapid 
increase in transplant demand has also occurred. In part, this is due to the rising incidence for 
diseases such as hepatitis C and type 2 diabetes, frequently leading to organ failure. 
Moreover, as surgical techniques, immunosuppressive regimens, and intensive care treatment 
methods improved, indications for organ transplantation have broadened. In developed 
countries, the human life span is constantly lengthening and increasingly older patients with 
sometimes complex comorbidities are now considered eligible for organ transplantation. 
  
Thus, it is evident that while advanced immunosuppressive regimens are used, many grafts 
continue to fail in the long term and individual patients may need multiple sequential 
transplants (Friedersdorff et al. 2016). Increasing pressure falls on transplant service–
providing organizations struggling with waiting lists. Disappointingly, thus far chronic graft 
failure research remains quite insufficient and protective interventions are lacking.  
 
In an effort to counter the urgent need for more organs, we have now seen a stepwise 
extension of donor criteria. Among the more recent techniques employed, transplant 
programs now rely not only on brain-dead donors but also donors following cardiac death. 
Compared to more conventional organ donation, grafts from these new donor groups are 
likely to be further stressed or injured prior to organ procurement. Accordingly, these grafts 
may experience more problems vis-à-vis initial function and may be at higher risk for failure in 
the long term. Yet, with careful recipient selection, even these unconventionally sourced 
transplants result in survival benefits for recipients. 
 
Since the early 1990s, the theoretical understanding of immunology has shifted from strict 
notions of self–non-self discrimination. It is now understood that mammalian immune system 
responses depend not only on recognition of foreign elements but also detection of “danger” 
signals encountered simultaneously. Necrotic cell death is one example of a danger signal. 
(Matzinger 1994). When considering the entire organ transplantation process, this shift 
highlights the pathological processes that take place early on while still in the operating 
theater. The early phases of the procedure are not only crucial to the initial graft function, but 
may also comprise an injurious primary event setting up a smoldering host response, 
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potentially culminating in repeated episodes of acute rejection and chronic graft failure much 
later. This view is supported by long-standing epidemiological evidence. 
 
In Finland, a clear majority of renal grafts originate from cadaveric donors and, thus, undergo 
various lengths of ischemic preservation followed by reperfusion. The resulting ischemia–
reperfusion (I/R) injury is exceedingly complicated and multifactorial. Despite intensive 
research, it also remains poorly understood. In general, organ preservation and I/R injury 
appear to activate cellular elements of innate immunity, soluble components of inflammation 
and coagulation, and paracrine mediators of epithelial, endothelial, and extracellular matrix 
homeostasis. Taken together, these early activated mechanisms work towards re-establishing 
intra-organ homeostasis, while simultaneously carrying the potential for considerable further 
local tissue damage and priming for subsequent attacks from the adaptive immunity arm.  
 
This study was conducted in a typical clinical transplantation practice setting in order to 
further elucidate select cellular and sub-cellular mechanisms leading to renal I/R injury. 
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REVIEW OF LITERATURE 
 
CLINICAL ASPECTS 
History 
 
In Finland, the first renal transplantation was performed in 1964. A mere year earlier, the 
Belgian surgeon Alexandre for the first time recovered and transplanted a kidney from a 
heart-beating brain-dead donor, well before any legislation regarding brain death was 
adopted (Machado 2005). Since then, more than 6000 renal transplantations have taken place 
in Finland, while annually 180 to 260 transplantations are performed.  
 
In 1971, Finland became the first country to adopt the concept of brain death both medically 
and legally. To date, more than 95% of all renal grafts originate from deceased brain-dead 
donors, exceeding 130 annually for the first time in 2016. However, during the last 25-year 
period, the number of recipients on the transplant waiting list has doubled, and exceeded 400 
at the time of writing (Scandiatransplant statistics 2013–2016). Waiting list times have 
similarly increased, with the median time spent waiting exceeding one year for the primary 
transplant. In the United States, the corresponding waiting time is at least threefold higher 
(2011 UNOS Annual Report). Over the past four years in Finland, a maximum of 11 patients each 
year died while waiting for a renal transplantation. An amendment to the Finnish law on 
organ transplantation, now assuming presumed consent for organ donation, was passed in 
2010. While the long-term effect of the amendment on the number of deceased donors 
awaits evaluation, the most recent annual figures appear to indicate a fair increase in the 
number of donor organs. Traditionally, donations from a spouse or living relative have not 
been popular and were usually considered only for pediatric recipients. Very recently, some 
momentum has been gained in this respect, however. 
 
Indications 
 
Absolute contraindications for renal transplantation are few. Each individual end-stage renal 
disease patient should be evaluated for transplantation, preferably during the pre-dialysis 
phase of disease (European Best Practice Guidelines Expert Group on Renal Transplantation 
2000). For the patient, transplantation offers the best renal disease–related prognosis as well 
as the best quality of life (Wolfe et al. 1999, Sarnak et al. 2003). The cost-effectiveness of 
transplantation is excellent, whereby expenditures associated with hemodialysis typically 
exceed transplantation-related costs in six months (Salonen et al. 2003). In Finland, almost all 
adult renal transplantation candidates already depend on maintenance dialysis once placed 
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on the transplant waiting list. Among pediatric candidates, a pre-emptive transplantation is 
sometimes performed without proceeding to dialysis. Table 1 summarizes the diagnoses 
related to terminal uremia for adult patients in Finland. 
 
Table 1. 
Distribution of diagnoses (%) related to end-stage renal disease leading to transplantation 
among adults in Finland during 2000–2009 and 2010-2016. 
 
Diagnostic group 2000-2009 2010-2016 
Glomerulonephritis 23 22 
Polycystic degeneration 18 17 
Type 1 diabetes 21 19 
Type 2 diabetes 5 7 
Tubulointerstitial nephritis 6 3 
Amyloidosis 2 1 
Other 20 22 
Undefined 6 8 
Total 100 100 
N 1772 1491 
 
Table courtesy of Associate professor Patrik Finne, MD PhD, director of the Finnish liver and kidney 
association. 
 
Organ donation 
 
In Finland, most kidney allografts originate from deceased brain-dead donors, while multi-
organ procurement techniques are routinely utilized. A considerable number of the grafts to 
date already result from the so-called expanded criteria donors (ECDs) as defined by the 
United Network for Organ Sharing (UNOS) (Metzger et al. 2003). Thus far, donors after cardiac 
death (DCD) or other non-heart-beating donors have not been used. Organs are allocated 
based on ABO blood group matching and human leukocyte antigen (HLA) tissue types, white 
blood cell cross match, and time spent on the waiting list. Finnish transplantation candidates 
enjoy benefits stemming from the relatively straightforward co-operation between the single 
transplantation center at Helsinki University Hospital and referring hospitals as well as the 
relatively short geographic distances between facilities. Both facts contribute to shorter 
preservation times. HLA matching is exclusively accomplished at a single center and, thus, 
does not result in excessive organ preservation time given that tissue types are typically 
already known prior to organ procurement surgery.  
 
The ideal allograft kidney donor is a young, living relative with a good HLA match. However, in 
Finland, living related donation (LRD) has not gained in popularity and a vast majority of adult 
renal grafts originate from deceased brain-dead donors. This contrasts somewhat to trends 
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elsewhere in Europe and particularly in the United States, where the number of living kidney 
donors surpassed the number of deceased donors in 2000 (2011 UNOS Annual Report).  
 
In comparison, the ideal deceased donor then is a younger person, who dies from a traumatic 
head injury isolated to the brain, leaving the thoracic and abdominal organs intact. In Finland, 
transplantation clinicians have recently raised concerns on the probable suboptimal use of 
potential donors (Salmela 2010). As such, even the most active donor-referring hospitals in 
Finland assessed by an internationally verified self-assessment program (Roels & Wight 2001) 
have found their performance to be less than optimal. Reflecting this, the best donor-
referring hospitals continually recognize and refer more than twice the number of donors per 
million population compared with the least-active referring units (Isoniemi H, lecture 
commentary, national transplantation convention, Helsinki 2012, Höckerstedt et al. 2005). 
Some estimates suggest that the number of Finnish patients on organ transplant waiting lists 
could be substantially reduced if all donor-referring hospitals performed optimally in terms of 
recognizing potential donors. Many reasons can be attributed to the suspected suboptimal 
recognition of donors. For instance, ever-increasing pressure towards better cost-efficiency in 
healthcare may leave potential donors overlooked, since deceased patients must be admitted 
to intensive care units until organ procurement occurs.  
 
By comparison, taking Norway’s example, a Nordic country much like Finland including its 
population size, improving the Finnish deceased donor identification appears possible. During 
the four-year period between 2010 and 2014 in Norway, 22 to 26 deceased donors per million 
inhabitants were annually recruited as opposed to the 17 to 22 per million inhabitants in 
Finland (Scandiatransplant statistics 2011–2016). This situation has been reversed in the last 
two years, however, as Finland identified 22 to 24 donors per million inhabitants compared 
with the Norwegian figures of 20 to 22 per million inhabitants. Complemented by an 
exceptionally active Norwegian program for living donation, significantly more kidneys have 
been historically transplanted in Norway; yet, in 2016, a higher total number of 
transplantations took place in Finland. The annual number of Norwegian patients who died 
while wait-listed compares with figures from Finland vis-à-vis the total number of patients 
wait listed for renal transplantation. Finland cooperates in Scandiatransplant, which is aimed 
at organ sharing across the Nordic countries (Grunnet et al. 2001). Yet, in practice, only about 
ten Finnish kidneys are exchanged annually through this collaboration (Salmela et al. 2004). 
All Nordic countries maintain their own national waiting lists. 
 
Since at least 2002, the so-called expanded criteria donor (ECD) for kidney donation has been 
relatively well described (Metzger et al. 2003). A considerable number of all kidneys donated 
in Finland already originate from ECD-derived sources. Compared with maintenance dialysis, 
the long-term feasibility of such transplantations has been documented (Ojo et al. 2001), 
although the overall relative risk of graft failure exceeds 1.7 compared with standard donor 
24 
 
kidneys. However, decision-making related to ECD kidney transplantation for individual cases 
remains unambiguous. For instance, relative mortality risk analysis shows that the short-term 
risk of death following transplantation is more than five times greater when compared to 
standard therapy with dialysis while waiting for a non-ECD kidney. This risk reverses only after 
226 days following transplantation and, thus, cumulative mortality does not equalize until 3.5 
years after ECD transplantation (Merion et al. 2005). Beyond this period, however, the ECD-
transplanted patient population begins to exhibit an overall survival benefit. In North America, 
these prognostic disparities led to policies calling for patient informed consent before 
becoming eligible for an ECD kidney (Metzger et al. 2003, Pomfret et al. 2008). Similar 
concerns were also raised in Europe (Bruzzone & Venettoni 2008). However, in the United 
States, a new policy utilizing the expedited allocation of ECD kidneys proved effective in 
addressing an organ shortage given the considerable rise in donations observed (Sung et al. 
2005). Furthermore, experiences from densely populated regions of Europe suggest that 
decision-making without strict criteria can be misleading and, consequently, viable grafts may 
be discarded (Friedersdorff et al. 2013). 
 
Due to the tremendous shortage of organs, even more marginal donors are currently utilized 
internationally. These include DCD donors and donors that die after brain death but before 
formal organ procurement procedures have been initiated (Rao & Ojo 2009). In select cases, 
transplantation using these presumably more compromised organs can be feasible, 
particularly when compared to patients still dependent upon maintenance dialysis (Summers 
et al. 2015). Concerns, however, regarding the appropriate use of such organs have been 
voiced, given that organ demand rather than careful planning before plantation tend to drive 
clinical practices (McDonald & Clayton 2013). The immediate costs of transplantation services 
increase when such marginal donors are utilized, although for kidney transplantation savings 
over maintenance dialysis remain relevant (Pomfret et al. 2008). In Finland, DCD donors have 
not been utilized thus far and the Finnish transplantation community maintains that the most 
expedient means of expanding the donation pool should focus on a concerted effort to utilize 
traditional donors more effectively and encouraging LRD in carefully considered and select 
cases (Salmela 2010). By contrast, Norway has adopted an alternate policy, becoming the first 
Nordic country to initiate DCD transplantations in 2015. 
 
Utilizing DCD donors inevitably introduces a significant warm ischemic component to the renal 
graft ischemia–reperfusion (I/R) injury. Experimentally, it is clear that increasing warm 
ischemia associates with more frequent primary non-functioning and delayed graft function 
(DGF) problems. However, in a relevant porcine model, even a 120-min warm ischemic insult 
did not translate into histological necrosis (Hosgood et al.  2015). Renal function deteriorated 
severely after just 60 min of warm ischemia, though. In any case, warm ischemia resistance of 
the human kidney could be better than previously expected (Parekh et al. 2013), and, thus, 
the hope of relying increasingly on DCD donor sources might be warranted. 
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Surgery 
 
In Finland, organ procurement surgery is performed exclusively by the surgical teams of the 
only transplantation center in the country. These teams travel to donor-referring hospital 
locations. Standard multi-organ procurement techniques are utilized, although perfused 
preservation techniques are not. 
 
The recipient operation is performed as described by Salmela (1994) preferably with end-to-
side vascular anastomoses to the recipient’s external iliac artery and vein. Traditionally, open 
ureteroneocystostomy is performed. Rarely, perhaps once a year, a situation emerges 
whereby renal transplantation is attempted, but, due to extreme recipient atherosclerosis, no 
renal graft can be implanted (Salmela, personal communication). 
 
 
Immunosuppression 
 
Modern immunosuppressive agents—primarily mycophenolate and tacrolimus—are currently 
used in addition to more traditional immunosuppression by cyclosporine, azathioprine, and 
corticosteroids. In the United States, horse-derived antithymocyte globulin (ATG) is often used 
as an adjunct to the initial immunosuppressive regimen (Hardinger 2006). In Europe, a similar 
product, rabbit-derived ATG, is available and used in select protocols with beneficial effects 
(Kaden et al. 2009). In this thesis, participating patients were recruited from a larger study, 
where two immunosuppressive agents not traditionally used in Finnish immunosuppressive 
induction were utilized and studied. These agents consisted of ATG (Fresenius) and the 
interleukin-2 (IL-2) receptor blocking antibody basiliximab (Kyllönen et al. 2007). 
 
Fresenius ATG, briefly, is a polyclonal antibody infusion created in rabbits immunized with 
Jurkat cells, an established line of immortalized T-lymphocytes originally obtained from the 
peripheral blood of a 14-year-old boy with leukemia. Different ATG preparations are each 
subject to research, since a multitude of clonal specificities are raised and the biological 
effects accordingly vary (Popow et al. 2012). Clinically, these preparations have been used in 
transplantation since the 1970s, whereby their main effects include not only T-lymphocyte 
depletion, but also non-depletive immunomodulation (LaCorcia et al. 2009). The adverse 
effects include cytokine release syndrome, which may require pre-treatment with 
corticosteroids (Kaden 2002, Denny et al. 2015). ATG preparations are more popular in the 
United States than in Europe, where interest in Germany in particular is more focused on 
developing new dosing algorithms. Of specific interest in this thesis, ATG preparations appear 
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to have an I/R injury protective efficacy beyond lymphocyte ablative effects. Namely, antibody 
specificities against selectin, integrin, and immunoglobulin superfamilies expressed in the 
endothelial cells and leukocytes have been identified (Rebellato et al. 1994, Michallet et al. 
2003). Furthermore, in an experimental setting, diminished leukocyte vascular adhesion with 
a better sustainability of blood flow has been observed by intravital microscopy (Chappell et 
al. 2006).  
 
Basiliximab is a recombinant murine/human chimeric nondepleting IgG1 monoclonal antibody 
directed against the IL-2 receptor. The IL-2 receptor was the first interleukin receptor 
characterized. It is present on the surface of activated T-cells, where upon IL-2 binding the 
receptor subunits converge to form a stable quaternary macromolecule with intracellular 
domains. Three intracellular signaling pathways are subsequently initiated. If the IL-2 stimulus 
is strong enough to reach a critical number of receptors triggered on the cell surface, T-cell 
DNA replication and mitosis occur (Malek & Castro 2010). Pharmacological intervention can 
be delivered in the form of basiliximab, which interrupts the abovementioned signal 
transduction chain and, thus, prevents the clonal expansion of alloreactive T-cells (McKeage & 
McCormack 2010). 
 
 
Delayed graft function (DGF) 
 
It is not uncommon for a transplant surgeon to observe immediate graft function. For 
instance, urine output may be observed already on the operating table, at times even from 
the sectioned end of the graft ureter awaiting suturing to the bladder. Unfortunately, the 
contrary is also common: Halloran et al. (1988) defined delayed graft function (DGF) as a 
plasma creatinine concentration ≥500mmol/l throughout the first week post-transplant, 
requiring more than one dialysis session during the first week post-transplant, or oliguria ≤1 
l/24 h for more than two days. Traditionally, this phenomenon has been viewed as the clinical 
manifestation of I/R injury. Furthermore, concrete evidence links DGF to inferior long-term 
outcomes (Ojo et al. 1997, Gill et al. 2016). Some researchers suggest that DGF associates 
with the same reduction in graft survival and graft half-life as a full HLA mismatch (Halloran & 
Hunsicker 2001). Accordingly, focusing on decreasing the cold ischemia time by accepting less 
optimal tissue matching may translate into more kidneys being transplanted (Port et al. 2002). 
In a study of more than 6000 renal transplantations, no significant tissue matching gains were 
identified when grafts travelled longer distances, but the associated longer cold ischemia time 
translated into worse long-term outcomes (Salahudeen et al. 2004). It appears, however, that 
HLA mismatching in itself may actually constitute a risk factor for DGF (Kamoun et al. 2008), 
thus highlighting the complex pathophysiology behind this clinical diagnosis. 
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In Finland, gradual improvements mitigating the incidence of DGF have been observed in 
recent decades. In the 1980s, nearly 40% of renal grafts suffered from DGF. However, 
procurement techniques evolved and related surgeries were performed almost increasingly 
and exclusively by dedicated transplant surgeons. This, in part, contributed to DGF incidence 
holding steady at 25%, despite the almost exclusive use of deceased donors (Salmela & 
Kyllönen 2007). However, because the use of ECD kidneys has become more commonplace, 
incidence is again rising. In a study from our institution comprising 176 consecutive deceased 
donor kidney transplantations, the observed incidence of DGF reached 40% (Hollmen et al. 
2011). As expected, DGF also translated into worse one-year graft survival at 90.0% vs. 99.1% 
in this particular patient cohort. 
 
Outcome 
 
Renal transplantations account for 80% of all solid-organ transplantations in Finland. 
Outcomes for primary renal transplantations are excellent, whereby 95% of kidneys function 
properly one year post-transplantation and 87% function properly five years following 
transplantation, rates comparable with international figures (Salmela et al. 2004). In Figure 1, 
improving prognosis of renal transplantation by five year periods over time is displayed. 
 
 
Figure 1. 
Trends for renal graft prognosis during the cyclosporine era in Finland, 1985 to 2009, n=3749. 
  
Table courtesy of Associate Professor Patrik Finne.  
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INNATE IMMUNITY 
 
The immune systems in jawed vertebrates are divided into the innate and adaptive arms 
(Figure 2). The complement system and phagocytic white cells comprise the innate arm, while 
lymphocytes in concert with their antibody production comprise the adaptive arm. Based on 
the contemporary research, however, this division is overtly simplified as the processes of 
antigen presentation, effector function selection, tolerance induction, and the resolution of 
inflammation inarguably involve both arms (Matzinger 1994, Nathan 2006). However, the 
relevance of this division can be appreciated in the types of responses to repeated stimuli. 
Innate immune responses are similar when repeatedly encountering the same stimulus. By 
contrast, adaptive immune responses evolve and enhance upon repeated stimulation. 
However, as adaptive immune responses are initiated by innate immune reactions, the innate 
immunity responses triggered within the context of allogeneic organ transplantation are 
especially important. 
 
 
Figure 2.  Simplified overview of the development of immune system cells.  
 
 
Adapted from “Systemic inflammation in preterm infants”, Riikka Turunen, academic dissertation ISBN 
978-952-92-5499-6 (pbk.) ISBN 978-952-10-5499-0 (PDF). Helsinki University Printing House, Helsinki 
2009. Reprinted with permission from the copyright holder. 
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Phagocytic white cells form the essential cellular elements of defensive innate immunity 
directed towards microbial infections or non-infectious tissue injuries. Phagocytes include 
monocytes/macrophages and neutrophilic polymorphonuclear white cells (that is, 
neutrophils). Eosinophils, basophils, and mast cells are traditionally considered a part of 
innate immunity, but their roles remain more obscure and are best described in relation to 
allergic and parasitic conditions. 
 
The cells of innate immunity respond to and are recruited by tissue through various distress 
signals that act in a paracrine manner. Distressed parenchymal and endothelial cells can 
secrete and display cytokines or other chemotactic molecules as a call for help. In addition to 
being actively secreted by the parenchymal distressed cells, activating signals may also be 
detected as conserved structural moieties found in microorganisms. Collectively, these 
structures are then called pathogen-associated molecular patterns (PAMPs). One such PAMP 
is lipopolysaccharide (LPS), a long-known potent biomolecule behind clinically observed 
dramatic symptoms of sepsis. In addition, host-derived non-infectious material can trigger 
innate immunity responses in a similar manner. In this case, molecular patterns are called 
damage-associated molecular patterns (DAMPs), often involving structures normally situated 
in the intracellular compartment and nucleus (Bianchi 2007, Lotze et al. 2007). Due to 
uncontrolled cell death or injury, these structural elements are released into the extracellular 
space and, thus, become visible to elements of innate immunity (Chen & Nuñez 2010).  
 
Innate immunity cells recognize PAMPs and DAMPs via an extensive array of conserved 
germline encoded receptors. Collectively, these receptors are called pattern recognition 
receptors (PRRs). To date, five classes of PRRs have been identified: toll-like receptors (TLRs) 
(Leifer & Medvedev 2017), nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLRs) (Claes et al. 2015), retinoic acid inducible gene I (RIG-I)-like receptors (RLRs) (Weber 
2015), C-type lectin receptors (CLRs) (Mayer et al. 2017), and absent in melanoma 2 (AIM2)-
like receptors (Burckstummer et al. 2009). PRRs have been intensely investigated since the 
landmark discovery of the toll gene’s importance in Drosophila fungal infection resistance in 
1996 (Lemaitre et al. 1996). In most cases, TLR activation causes dimerization of TLRs through 
their ligands, leading to intracellular signal transduction (De Nardo 2015). Today, it is 
understood that different PRRs can function together to form various heterodimers or 
participate in the formation of highly complex intracytosolic signaling aggregates with other 
proteins to form so-called inflammasomes (Latz et al. 2013). The formation of higher-order 
complexes, in part, serves to diversify the array of ligands that PRRs can recognize. PRR-
triggered signal transduction pathways exhibit complex downstream regulation at the 
cytosolic and transcriptional levels. Broadly, the recognition of external and intrinsic danger 
signals by PRRs culminates in the activation of specific transcription factors or proteolytic 
pathways, resulting in the production of pro-inflammatory mediators such as the tumor 
necrosis factor (TNF) and IL-1. 
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Of special interest within the context of transplantation is the initiation and propagation of 
sterile inflammation. In solid organ transplantation, the most obvious injurious element is 
organ preservation–related ischemia and subsequent I/R injury. Prototypical DAMPs resulting 
from cells losing their membrane integrity include the chromatin-associated protein high-
mobility group box 1 (HMGB1) (Lau et al. 2014), S100 calcium-binding proteins (Foell et al. 
2007), heat shock proteins, purine metabolites, and uric acid. To further complement the 
recognition of these endogenous elements by PRRs, specific receptors for DAMPs also exist. 
One such receptor is the multiligand receptor for advanced glycation end products (RAGE), 
which recognizes products accumulating under high-oxidant stress conditions (Chen & Nuñez 
2010, Dessing et al. 2012). In the context of renal I/R injury, TLR-4 has increasingly been 
shown to play an important role (Kruger et al. 2009, Zhao et al. 2014). 
 
Neutrophils 
 
Neutrophils represent the first-line of defense against invading microbes. Their most natural 
adversaries consists of hostile bacteria, which neutrophils recognize aided by PRRs. 
Neutrophils are the most numerous leukocytes in the blood, although they are not typically 
present in healthy tissues and, as such, serve as the hallmark of acute inflammation in 
histological sections. 
 
The organelle apparatus of a mature neutrophil appears not to carry extensive synthetic 
capabilities since the Golgi apparatus is small, ribosomes and mitochondria remain sparse, 
and the rough endoplasmic retinaculum is altogether absent. However, some unforeseen 
capabilities, including cytokine production, are now understood to occur (Nauseef 2016). In 
large part, the actions of neutrophils rely on the timely expenditure of preformed granules, 
whereby each neutrophil contains roughly 200 granules (Cowland & Borregaard 2016). These 
organelles fall within the categories of primary, secondary, and tertiary granules, as well as 
secretory vesicles. More simplistically, the primary granules contain myeloperoxidase, 
bactericidal permeability increasing protein (BPI), defensin, elastase, and cathepsin G. 
Secondary granules contain lactoferrin and lysozyme. Finally, tertiary granules contain 
cathepsin and gelatinase B (also known as matrix metalloproteinase 9, MMP-9). Secretory 
vesicles, then, represent a quickly available reservoir of adhesion molecules, since the 
molecules contained are already membrane-bound so that their adhesive domains point 
towards the vesicle center. Vesicle fusion with the outer-cell membrane then reverses 
molecule orientation. Neutrophils are relatively short-lived cells with a life span estimated at 
between 24 h and 5.4 days. The make of neutrophils reflect their principal mission—they are 
armed for a one-way microbicidal mission.  
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Typically, when a blood-borne neutrophil encounters activated endothelium with increased 
adhesion molecules and chemokines, it establishes a cascade of adhesive interactions with 
endothelial cells lining the lumen of the postcapillary venular walls, ultimately exiting the 
blood vessel (Ley et al. 2007, Muller 2016). Initially, neutrophil is captured and weak selectin-
mediated adhesions form allowing it to roll over the endothelial surface. Rolling slows the cell 
down, thus permitting surveillance for more chemotactic or other activating signals. If the 
stimuli encountered are sufficiently strong, neutrophil becomes primed, thereby allowing for 
the full potential use of its cellular machinery. On the neutrophil surface, a conformation 
change of constitutively displayed surface integrins takes place, while additional integrin 
adhesion molecules stored in secretory vesicles may also mobilize to the surface. Neutrophil 
integrins including CD11b bind ligands such as endothelial ICAM-1 and mediate firm adhesion 
halting the cell. Then, neutrophil begins MAC1-dependent crawling along the chemotactic 
gradient on the endothelium looking for a suitable site to transmigrate. Transmigration is 
preferentially paracellular—that is, at the endothelial cell–cell junctions. The transcellular 
route through endothelial cells may also be employed. This mode of transmigration is more 
time-consuming despite endothelial cells forming transmigratory domes, thus facilitating the 
process (Figure 3). After transmigration, neutrophils must cross the basement membrane, a 
process where granule-contained MMPs become relevant (Delclaux et al. 1996). 
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Figure 3.  
Updated classic neutrophil recruitment cascade. 
 
Adapted from Kolaczkowska E et al. “Neutrophil recruitment and function in health and 
inflammation”. Nature Reviews Immunology 2013; 13:159–175. Reprinted with permission from the 
copyright holder. 
 
Once transmigration is achieved, three potential actions are open to neutrophils, as reviewed 
by Nathan (2006). 
 
First, crawling along the concentration gradient of the chemotactic stimulus, neutrophils 
attempt to find, bind to, and initiate phagocytosis, thereby killing microbial targets (Roos et al. 
2003). If successful, they continue until sufficiently clearing infectious organisms, then they 
can shift towards shutting off inflammation and promoting replicative wound healing.  
 
Second, if neutrophils cannot make contact with consumable microbes sufficiently quickly but 
still sense inflammatory or infectious surroundings, they release their toxic armament upon 
degranulation and attempt to kill the intruder at a distance. In this all-out kamikaze response, 
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even their nuclear material remains behind as a lysozyme-decorated, bacteria-snaring 
neutrophil extracellular trap (Brinkmann & Zychlinsky 2007). In this mode, the potential for 
substantial host tissue damage exists, since destructive proteolytic enzymes are released 
freely. In essence, this type of inflammatory activity leads to the formation of pus, the 
liquefying properties of which are well known. 
 
Third, if neutrophils do not find consumable microbes and do not sense further signs of 
danger, they identify the incident as a false alarm and undergo apoptosis.  
 
The modes of action described above include exceptions, however. Recently, confocal 
intravital microscopy in the context of I/R injury identified the reverse transmigration of 
neutrophils in vivo (Woodfin et al. 2011). Furthermore, those results suggested that 
neutrophils reverse-transmigrating from inflamed tissue to the vessel lumen might contribute 
to the dissemination of systemic inflammation and injury to secondary organs.  
 
Lactoferrin 
 
Lactoferrin is a transferrin family multifunctional protein found in bodily fluids such as human 
milk, blood plasma, tears, saliva, and nasal secretions. As implied by its name, lactoferrin 
transfers iron to cells and, in part, regulates the concentration of free iron in bodily fluids. In 
addition, lactoferrin exhibits considerable antimicrobial activity. Its capacity to limit bacterial 
growth has been thoroughly studied, and relates in part to iron deprivation from growing 
bacterial cells (Drago–Serrano et al. 2017). Binding to specific receptors along the outer 
bacterial cell membrane provides another defensive mechanism, since in this bound form 
lactoferrin can promote bacterial oxidization via the formation of peroxide. Membrane-bound 
lactoferrin also opsonizes bacteria for phagocytosis (Farnaud & Evans 2003). The proteolysis 
of lactoferrin appears to yield stable antimicrobial peptides potentially exceeding the potency 
of intact lactoferrin (Saito et al. 1991). The antimicrobial activity of peptide fragments seem 
unrelated to iron chelation. In addition, the antifungal and antiviral properties are 
demonstrably distinct from the antibacterial activity of lactoferrin.   
 
In neutrophils, specific granules contain lactoferrin. As a one facet of neutrophil activation, 
degranulation process occurs, whereby lactoferrin is released to the cell’s surroundings 
(Faurschou & Borregaard 2003). Thus, lactoferrin readily detectable in blood can serve as an 
index of upstream neutrophil activity. 
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Matrix metalloproteinase 9 (MMP-9) 
 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases capable of 
breaking down components of the extracellular matrix (Viappiani et al. 2006). As such, MMPs 
have been extensively investigated given their involvement in numerous physiological and 
pathological processes. For instance, they play a role in extracellular matrix homeostasis, the 
spread of neoplastic tumors and metastases, the migration of inflammatory cells (Verollet et 
al. 2011), and the control of inflammatory vascular permeability. Neutrophils contain a readily 
available source of MMP-9 in their secondary and tertiary granules (Wang et al. 2005). 
Actively secreted MMP-9 represents a major factor in trans-basement membrane neutrophil 
migration (Delclaux et al. 1996). Renal MMP-9 appears to increase during experimental renal 
ischemia (Caron et al. 2005, Caron et al. 2005, Bellini et al. 2007, Basile et al. 2004). By 
destroying the extracellular matrix, MMP-9 may increase microvascular leakage and further 
enhance the extravasation of neutrophils during renal reperfusion injury (Sutton et al. 2005). 
Indeed, MMP inhibition provides protection from experimental renal I/R injury (Kelly et al. 
2004, Wang et al. 2005, Novak et al. 2010). However, evidence also exists suggesting that 
processes leading to the reoxygenation of hypoxic tissues may depend on MMP-9 delivery via 
neutrophils (Christoffersson et al. 2012). 
 
Tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) 
 
The tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) belongs to the family of 
physiological tissue inhibitors of matrix metalloproteinases (TIMPs). TIMP-1 inhibits MMP 
activity by blocking the MMP catalytic core. Persistently elevated levels of TIMPs have been 
described in the context of renal transplantation, possibly triggered by the donation or 
implantation processes. The resulting diminished MMP activity, in turn, impacts the 
development of chronic allograft nephropathy (Ahmed et al. 2012).  
 
Monocytes/macrophages 
 
Monocytes are blood-borne macrophages and, as such, are relatively inactive. They travel to 
the target host tissue, where they differentiate into tissue-resident macrophages and adopt 
their phenotypic form, which is highly variable depending on the host tissue. In addition, 
macrophages are versatile cells with considerable longevity compared to neutrophils, capable 
of surviving for months at best. Macrophages take on the role of removing necrotic cellular 
debris or worn out cells (including neutrophils). They are also capable of functioning as 
antigen-presenting cells and, thus, play a key role alongside dendritic cells in initiating 
adaptive immune responses. Stimulated by T-lymphocyte-derived lymphokines, macrophages 
can also further differentiate into a more aggressive form (“armed macrophage”) and protect 
against malignantly transformed cells or cells infected with fungi or parasites. Finally, 
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macrophages shut off inflammatory responses and participate in wound healing and tissue 
repair. 
 
Complement system 
 
Three different pathways activate the complement system, all of which converge in the 
formation of C3 and, subsequently, the membrane attack complex (MAC). The complement 
system provides an important link between the innate and adaptive immunity arms since its 
activation via the classical pathway involves the binding of an antibody. The role of the 
complement system in the humoral rejection of transplantations has been extensively 
described, while less is known about its interaction with T-cell cytotoxic responses. Growing 
interest in I/R injury control revealed the importance of the complement system in this 
respect as well (Carroll et al. 2005, Zhang & Carroll 2007). In renal transplantation–related I/R 
injury, complementary activation via an alternate pathway and the lectin-binding pathway 
appear more important than activation via the classic pathway (Damman et al. 2008). 
 
  
36 
 
COAGULATION AND HEMOSTASIS 
  
Maintaining blood fluidity depends on the activity of the endothelial cells. As a boundary layer 
between blood and the parenchymal cells, endothelium also plays a key role in the 
recruitment of inflammatory cells. The endothelial cells comprise an “organ”, which weighs 
about 720 g in an adult, with more than 600 g of this cell mass dedicated to the capillaries. 
The overall endothelial surface area has been estimated at 3000 to 6000 m2 (van Hinsberg 
2012).  
 
The obvious goal of blood coagulation is achieving hemostasis after an injury to a blood 
vessel. When a vascular wall breach occurs, blood elements come into contact with structures 
not encountered within an intact vasculature. The most notable structures include collagen 
and tissue factor. Platelets bind collagen via specific receptors and aggregate together to form 
a platelet plug. Simultaneously, activated platelets and tissue factor exposed from the 
subendothelial space trigger a coagulation cascade culminating in the formation of fibrin, 
which serves to further stabilize the clot. These processes occur simultaneously and are 
termed primary and secondary hemostasis, respectively. The process of fibrinolysis 
concomitantly initiates and represents the resolution phase as the original violation is 
controlled. 
 
Primary hemostasis 
 
Primary hemostasis results in the formation of a platelet plug. When the vascular wall is 
compromised, extracellular matrix elements are exposed to blood-borne cellular and acellular 
components. Platelets bind to the exposed extracellular matrix through a multitude of 
adhesive molecules, including their glycoprotein receptors that bind collagen. The platelet 
functional activation leading to the further recruitment of additional platelets and the 
activation of the coagulation cascade are complemented by the changing shape of the 
platelets from spherical to stellate. 
 
Secondary hemostasis 
 
The coagulation cascade related to secondary hemostasis consists of a series of enzyme 
precursors that circulate freely in the blood stream, typically called coagulation factors. As the 
cascade is triggered, the active form of the coagulation factor catalyzes the activation of the 
next factor in the series, resulting in a spatially controlled reaction amplification, thus creating 
the so-called thrombin burst and ultimately forming insoluble fibrin. The cascade 
encompasses both negative and positive feedback loops that prevent the uncontrolled spread 
of activation throughout the vasculature.  
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In short, when the endothelial disruption triggers the tissue factor (TF) pathway, factor VII 
makes contact with TF, yielding the activated complex of TF and FVIIa. The TF–FVIIa complex 
activates FIX and FX. FXa and FVa aggregate to form a prothrombinase complex, which then 
catalyzes prothrombin conversion to thrombin. The creation of thrombin in large enough 
quantities is essential, since thrombin catalyzes the final step of cleaving fibrinogen to 
insoluble fibrin, thus reinforcing the platelet plug of primary hemostasis. Thrombin also 
represents the most important site of feedback regulation for the coagulation cascade 
(described below). Figure 4 provides a schematic representation with some of the regulatory 
elements shown.  
 
Figure 4.  
Blood coagulation cascade. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Joe Dunckley / Wikipedia.  
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The newer cell-based model of coagulation expands the cascade model encompassing a 
multitude of cellular elements that inevitably participate in coagulation processes in vivo. 
Several bleeding or thrombotic clinical disorders remain theoretically unexplained, if the 
impact of phospholipid bilayers remains unconsidered. Today, the presence of polarized 
phospholipid bilayers and incorporated proteins represent a proven regulatory element in 
coagaulation (Smith 2009). 
 
Aside from its central role in blood coagulation, thrombin is also recognized as one of the 
factors contributing to perioperative inflammatory syndromes (Raivio et al. 2006, Untch et al. 
2008). Prothrombin fragment F1+2 is a byproduct of the cleavage of prothrombin to thrombin 
readily detectable in blood. Thus, it can be used as an indicator of the ongoing thrombin 
formation. 
 
Endogenous anticoagulation 
 
Activated protein C (APC) performs widespread functions in regulating blood coagulation and 
inflammation. Protein C (PC) is a K vitamin–dependent glycoprotein that circulates in the 
blood in the zymogenic or inactive form. Activation takes place upon binding to thrombin and 
is amplified by complexion with thrombomodulin and the endothelial protein C receptor 
(EPCR) on the endothelial surfaces. In the active form, APC exerts its anticoagulant properties 
through the proteolytic inactivation of coagulation factors V and VIII. As such, PC–APC is 
regarded as the most important naturally occurring anticoagulant in humans, whereby its 
clinical importance is highlighted by the fatal course of neonatal protein C deficiency when 
left untreated (Esmon & Schwarz 1995). 
 
The tissue factor pathway inhibitor (TFPI) is another major physiological regulator of TF-
induced blood coagulation. TFPI affects coagulation by directly inhibiting factor Xa and by the 
FXa-dependent inhibition of the TF–FVIIa complex. In this interaction, protein S works as a 
cofactor in the direct inhibition of FXa (Ellery & Adams 2014). 
 
Antithrombin represents yet another major endogenous anticoagulant, which degrades 
several coagulation factors including thrombin, FIXa, FXa, FXIa, and FXIIa. Its actions are 
exploited clinically, since an affinity towards the antithrombin substrates can be enhanced 
quite substantially using different heparin preparations. 
 
Fibrinolysis 
 
As soon as some fibrin has been deposited within the vascular network, concurrent 
fibrinolysis occurs, aimed at protecting against excessive coagulation and allowing for 
revascularization. To this end, the liver synthetizes plasminogen, of which plasmin is created 
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via proteolytic cleavage by the endothelium-synthesized tissue plasminogen activator (tPA). 
Plasmin cleaves fibrin into fibrin degradation products. 
 
D-dimer is a small soluble fibrin degradation product found in the blood. The laboratory 
determination of D-dimer enjoys wide clinical use as a marker for increased fibrin turnover. 
The possible effects on inflammation, however, remain poorly understood. Yet, for other 
fibrin fragments, such fibrin fragment E, some evidence of a pro-inflammatory activity exists. 
The impact of these fragments in vivo is yet to be determined (Jennewein et l. 2011). 
 
Along with plasmin, the tissue plasminogen activator (tPA) is a key enzyme in fibrinolysis and 
blood clot dissolution. Produced primarily by endothelial cells, tPA functions by converting 
blood-borne inactive proenzyme plasminogen into active serine protease plasmin, which, in 
turn, degrades fibrin. Normally, only minute concentrations of tPA circulate. Under normal 
circumstances, tPA endothelial secretion falls under complex hormonal and physical factor 
controls. The enzymatic activity of tPA greatly increases in the presence of fibrin, thereby 
localizing the fibrin-degrading activity of plasmin on fibrin surfaces (Loscalzo 1988). 
Experimental evidence points towards the role of tPA in neutrophil trafficking in renal I/R 
injury, potentially representing a target for therapeutic intervention (Roelofs et al. 2006). 
 
Plasminogen activator inhibitor 1 (PAI-1) plays an important role in maintaining the delicate 
equilibrium between hemostasis and blood clot dissolution (Brown 2010). PAI-1 is a serine 
protease inhibitor functioning as the principal inhibitor of tPA. The main site of PAI-1 
production is the endothelium, although other sources have also been recognized. Along with 
tPA, MMP actions are also inhibited by PAI-1 (Ha et al. 2009).  
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INFLAMMATION 
  
Inflammation is the body’s response to tissue injury, whether from an infectious etiology or 
not. Because multicellular organisms have faced constant microbial challenges for several 
hundred million years, quite potent protective systems have evolved. However, since the 
fundamentals of biochemistry are preserved through the evolution of all genetic material–
containing organisms, the machinery used to attack and kill an invader also carries a 
considerable potential to harm the host as well. This dictates the need to maintain continuous 
homeostatic control over such mechanisms, only permitting activation in a strictly controlled 
manner, both spatially and temporally (Nathan 2006). In the wild or in nature, a tissue injury 
without concomitant microbial infection or at least contamination is virtually impossible. In 
the modern world, however, injury without infection is possible to some extent in the 
unnatural environment of a sterile operating theater.  
 
Histologically acute inflammation is often characterized by tissue neutrophil infiltration. 
Neutrophils are followed by blood monocytes that mature into inflammatory macrophages. 
Resolution is characterized by the clearance of neutrophils and the tissue mononuclear cell 
population’s return to a normal pre-inflammatory state.  
 
As neutrophils commit to an inflammatory action, several security checkpoints need to be 
passed. These involve contact with pro-inflammatory molecules, pathogens, or DAMPs as well 
as cellular contact including activated endothelium, activated lymphocytes, and activated 
macrophages or dendritic cells (Nathan 1987). When these prerequisites are met, neutrophils 
are activated and their longevity is dramatically increased. Having adopted a pro-
inflammatory phenotype, neutrophils also recruit more leukocytes to the scene. Recent 
evidence suggests that among the neutrophil population, different subsets with varied 
patterns of cytokine secretion may exist and these subsets may differ in their expression of 
TLRs and integrins. Experimental data indicates that differing neutrophil subsets play a role in 
shaping the course of the immunological response depending on the type of challenge at 
hand (Kolaczkowska & Kubes 2013). 
 
Just as mobilizing and recruiting inflammatory armamentum quickly when needed is 
important, cessation and resolution must also promptly follow in order to avoid host-tissue 
destruction (Nathan 2002). A body of evidence suggests that immediately during the 
beginning phases of acute inflammation, a preprogrammed end to the inflammatory process 
is initiated. The biochemical basis for this may lie in the regulation of eicosanoid family 
bioactive lipid mediators, so that a shift from the synthesis of pro-inflammatory 
prostaglandins to the synthesis of resolution and anti-inflammation promoting lipid mediators 
takes place. In this context, new classes of mediators—lipoxins, resolvins, and protectins—
have been identified (Serhan & Savill 2005, Serhan 2008). 
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Due to the many intruder shapes and forms, a tremendous amount of redundancy and 
overlapping mechanisms of mammalian inflammatory and immune systems has evolved, of 
which the abovementioned only touch upon briefly. Hence, pursuing successful whole organ 
transplantation, clinicians face the formidable tasks of simultaneously inhibiting any 
inflammatory injury to the graft and protecting the graft and recipient from infectious risks. 
Inflammatory system redundancy renders escaping detection difficult for pathogens, while 
also making it difficult for transplantation physicians to shut down these systems safely, even 
for a short while, in order to perform implantation surgery. 
 
Donor inflammatory response 
 
Brain death induces a profound inflammatory response in the donor as well as serious 
perturbations in other homeostatic systems, including the blood pressure and hormonal 
control. These can be managed to a certain degree, but typically require intensive care as well 
as technical resources and personnel (Westendorp et al. 2011). Some claim that managing 
brain-dead donors is the most neglected area of transplantation medicine. 
Contrary to outside perceptions, brain death is not a static condition (Bos et al. 2007). 
Cerebral injury or trauma is followed by an increase in intracranial pressure with immediate 
hormonal changes. The increasing intracranial pressure triggers parasympathetic activity, 
resulting in systemic hypotension. Hypoperfusion and ischemia of the peripheral organs may 
also occur at this stage (Figure 5). When the brain stem is herniated, sympathetic stimulation 
together with persistent parasympathetic activation causes further disturbances, including 
bradycardia, hypertension, and an irregular breathing pattern. Collectively, as early as 1902 
these disturbances were labeled the Cushing reflex (Cushing 1902). When the vagal 
cardiomotor nucleus becomes affected, solitary sympathetic stimulation supervenes. At this 
stage, a massive systemic release of catecholamine hormones occurs. This “catecholamine 
storm” then leads to a hypertensive crisis. Intense vasoconstriction in the peripheral vascular 
beds, in turn, can lead to end organ–level parenchymal hypoxemia. Experimentally 
catecholamine-induced vasoconstriction may cause a dramatic decrease in the renal blood 
flow due to an increase in vascular resistance (Herijgers et al. 1996). All tissues suffering from 
oxygen deprivation rely on anaerobic energy metabolism, which, in turn, leads to the 
production of lactate and anaerobic energy metabolism intermediates. The accumulation of 
these products leads to later vasodilation, which then in conjunction with other perturbations 
(e.g., heart failure) may cause hemodynamic collapse. This subjects peripheral tissues to 
further oxygen deprivation creating a vicious circle. 
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Figure 5.  
Proposed model for the (patho)-physiological changes associated with brain death. 
 
 
 
 
Adapted from Bos EM et al. “Kidney grafts from brain dead donors: Inferior quality or opportunity for 
improvement.” Kidney Int 2007; 72:797–805. Reprinted with permission from the copyright holder. 
 
 
Experimental studies on brain death have pinpointed pituitary failure as a source of major 
hormonal perturbations. In humans, however, data are scarcer. Somewhat better 
understanding exists regarding the appearance of diabetes insipidus as antidiuretic hormone 
(ADH) production diminishes. The resulting polyuria contributes to hypovolemia and problems 
maintaining an adequate perfusion pressure (Chen et al. 1999). Treatment with thyroid 
hormones, ADH, and insulin as well as the use of corticosteroids is often deemed necessary, 
although the resulting clinical outcomes appear somewhat inconclusive. 
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Growing evidence indicates that systemic inflammatory changes following brain death occur 
(Takada et al. 1998). The primary reason behind systemic inflammation remains unclear, 
however. Possible sources for the observed elevation in inflammatory mediators in the blood 
stream include an ischemic brain, an ischemic intestine, bouts of anaerobic metabolism, 
extreme swings of blood pressure, poor control of blood glycemia, and the release of 
peripheral neuropeptides no longer under cortical control (Floerchinger et al.2012).   
 
Among other inflammatory responses, brain death has also emerged as an important inducer 
of complement activation. The data on the complement system’s role in renal I/R injury 
remain somewhat contradictory, however. Admittedly, experimental interventions targeting 
various complement components have proven protective against renal I/R injury. However, it 
is also noteworthy that the kidney itself has emerged as a site of marked complement 
production and many renal cellular structures exhibit a complement-producing capacity in 
vitro (Jager et al. 2017).  
 
Today, the end-organ effects of brain death are not understood in detail in humans, but direct 
evidence of donor kidney injury has been demonstrated. Compared to living donor kidneys, 
differences in leukocyte infiltration, endothelial adhesion molecules, and inflammatory gene 
expressions are observed (Nijboer et al. 2004). The mechanisms behind clinical complement-
related injury are currently being examined (van Werkhoven et al. 2013). 
 
Ischemia–reperfusion (I/R) injury 
 
Persistent ischemia of the tissue induces cellular responses. On the one hand, these responses 
work to eliminate (microbial) invaders and restore oxygenation by activating inflammatory 
responses and, on the other hand, attempt to help cells adapt to and withstand hypoxia 
through anti-inflammatory, anti-apoptotic, and regenerative responses. The cellular oxygen-
sensing signaling pathway of prolyl hydroxylases (PHD) and the hypoxia-inducible factor (HIF) 
lie at the heart of hypoxia-induced responses (Eltzschig & Carmeliet 2011). Examples of PHD–
HIF pathway pro-inflammatory signaling include the transcriptional promotion of the pro-
inflammatory nuclear factor kappa B (NF-κB) and TLRs, and this pathway also impacts human 
renal transplantation (Rosenberger 2007). One important result stems from the conversion of 
the endothelium from the anti-adhesive and anticoagulation phenotype to the adhesive and 
procoagulant phenotype. The capability of the PHD–HIF pathway to help withstand hypoxic 
milieu, then, is in part mediated by the transcriptional promotion of heat-shock proteins. The 
abovementioned examples involve many important messenger molecules and intermediates 
such as adenosine, netrins, and sphingolipids (Rosenberger et al. 2009, Bartels et al. 2014). 
Altogether, cellular hypoxia signaling has proven to be a very complex process and 
intensifying research has identified new regulatory elements (Furuichi et al. 2008). Obviously, 
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the field carries significant translational relevance since ischemia-protective pharmacological 
interventions remain insufficient and injury prophylaxis rather than treatment would appear 
advantageous (Eltzschig & Eckle 2011). 
 
When perfusion is regained following a period of ischemia, paradoxically tissue injury 
exacerbation and profound inflammatory responses tend to occur. Many overlapping 
mechanisms may contribute to this paradox. As blood flow is reinstituted, a low oxygen milieu 
is suddenly reversed to a high oxygen milieu. This favors the creation of reactive oxygen 
species (ROS), highly reactive molecules capable of inflicting, for instance, cellular protein, as 
well as lipid and DNA damage (Kosieradzki & Rowiński 2008). The NADPH oxidase enzyme, 
expressed by virtually all inflammatory cells, may generate cytotoxic ROS peroxynitrite. In 
addition, H2O2 derived from O2 dismutation, in turn, results in toxic hydroxyl radicals via a 
Haber–Weiss reaction, facilitated by the increased availability of free iron in ischemia (Kehrer 
2000). 
 
Due to the ischemia-induced inflammatory signaling activity, the accumulation of 
inflammatory cells follows the restoration of blood flow. Innate immune cells dominate the 
cellular infiltrate composition during the early phases of reperfusion. The contributions of 
separate cell types to the ensuing tissue damage are not unambiguous. For example, recruited 
monocytes appear to beneficially participate in the healing processes after an ischemic injury. 
Neutrophils, by contrast, are often detrimental since their vast numbers and cellular makeup 
carry significant destructive potential. However, it is also possible that too few neutrophils  
may not allow for the adequate clearance of debris and subsequent tissue repair, with 
potential negative implications particularly in the context of transplantation, where 
alloantigens are present. In any case, infiltrating cells exhibit pro-inflammatory phenotypes 
including a heightened cytokine production and the upregulation of TLRs, of which TLR4 
specifically has been studied within this context (Jang & Rabb 2009). 
 
I/R injury also initiates a considerable adaptive immune response (Boros & Bromberg 2006). 
Lymphocytic cellular infiltrates play different roles in I/R injury (Linfert et al. 2009). CD4+CD8+ 
T cells appear to carry detrimental roles in various ischemia reperfusion settings. T-reg cells, 
by contrast, attenuate I/R injury in experimental settings. Dendritic cell recruitment 
represents one of the major immune responses associated with transplantation-related I/R 
injury and this type of response accompanies even syngeneic transplantations (Schlichting et 
al. 2006). 
 
In addition, subcellular elements may contribute to I/R injury. Platelet aggregation and 
activation yields pro-inflammatory and procoagulant products and, in part, participates in 
complement activation. Complement activation, in turn, may propagate due to the 
recognition of ischemia-induced neoepitopes via naturally occurring antibodies. Complement 
activation then leads to further neutrophil recruitment and tissue injury. 
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Ischemia and reperfusion in transplantation 
 
Organ ischemia of some duration is inevitable in deceased-donor transplantation. In addition 
to physical cooling, several preservation solutions are employed to preserve organ viability 
(Wilson et al. 2006). Common to these solutions is their intracellular compartment-like 
electrolyte content aimed at diminishing cell swelling caused by the cell membrane ion pumps 
progressively ceasing their action when adenosine triphosphate (ATP) is depleted. A buffering 
capacity is also added in order to counter lactate creation, since cells rely on anaerobic energy 
metabolism during preservation (Lee & Mangino 2009). Recent organ preservation advances 
include machine perfusion methods with or without hypothermia. The feasibility of these 
methods remains to be determined, however (Timsit & Tullius 2011). 
 
Several strategies in solid organ transplantation contexts have been investigated in order to 
prevent the pathological chain of events described above. These include ischemic 
preconditioning, leukocyte depletion (Sievert 2003), manipulation of complement activation, 
manipulation of inflammatory signaling, adhesion molecule blockade, and the administration 
of antioxidants. These interventions all exhibit some benefit, particularly in experimental 
settings, whereby clinical trials often result in disappointing results. As such, none of these 
interventions have been widely adopted thus far. 
 
No reflow phenomenon 
 
The no reflow phenomenon refers to a state where macro- or microvascular blood flow is not 
effectively restored after declamping of the allograft vasculature. Difficulties in the reflow of 
the larger vessels result from errors in surgical technique and clot formation due to 
inadequate flushing during procurement. In addition, de novo thrombosis may occur 
particularly in recipients with undiagnosed hypercoagulation disorders.  
 
At the microvascular level, differing patterns of the no reflow phenomenon may be observed. 
The phenomenon may occur in a more or less regional manner (Yamamoto et al. 2002). 
Capillary no reflow may result from microthrombosis or endothelial blebbing, impaired 
vasorelaxation, and capillary plugging due to leukocytes (Snoeijs et al. 2010). During tissue 
inflammation, leukocyte trafficking normally takes place in the postcapillary venules. These 
vascular sites are well suited to trafficking for several reasons. Firstly, the blood flow in the 
postcapillary venules is slow. This results in red cells forming columns or rouleaux, which then 
populate the axial center of the blood vessel lumen, pushing the white cells to the sides and 
into contact with the endothelium. Secondly, because postcapillary venules are also sites for 
endothelial adhesion molecule presentation, white cell rolling, firm adhesion, and 
transmigration can effectively take place. Thirdly, postcapillary venules have a sufficient 
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diameter enabling the maintenance of forward blood flow even in situations where 
substantial endothelial surfaces become involved in the process of leukocyte margination and 
transmigration. 
 
Alas, because tissue ischemia is prolonged, capillaries also begin expressing adhesion 
molecules (Yamazaki et al. 1993). This carries adverse consequences during reperfusion. Being 
pancake shaped, red cells can fold up upon themselves (like rolled crepes) and squeeze 
through the capillaries even when some endothelial swelling is present. The case is different 
for the spherical-shaped white cells, however. Even during normal capillary blood flow, white 
cells are sausage shaped when squeezing through capillaries and, thus, create a wide contact 
area with the endothelium. When endothelial cells are swollen or adhesion molecules are 
present, the white cells are effectively stopped inside the capillaries preventing further blood 
flow (Engler et al. 1983). When this happens, a progressively larger proportion of the blood 
flow is diverted upstream from capillaries, taking place through larger-diameter arteriovenous 
connections. Measured from the major graft-supplying artery, the blood flow may continue 
with little noticeable interference, although seriously jeopardized blood flow at the capillary 
level means prolonged tissue reliance on anaerobic metabolism. 
 
Protein C: activated protein C (APC) 
 
Aside from regulating blood coagulation, APC also possesses several anti-inflammatory 
properties exerted on the endothelial cells and leukocytes (Levi et al. 2012). These serve to 
downregulate the production of pro-inflammatory cytokines and to reduce the adhesion and 
activation of leukocytes. Anti-inflammatory effects largely depend on EPCR-bound APC 
signaling via protease-activated receptor 1 (PAR-1). Broadly, anti-inflammatory APC signal 
transduction cascades converge at the level of NF-κB, the prototypical pro-inflammatory 
transcription factor (Esmon 2012). Local direct effects on the rate of neutrophil recruitment 
may be mediated in part by decreasing the thrombin-dependent mobilization of the Weibel–
Palade bodies. In the endothelial cells, the Weibel–Palade bodies represent cytosolic storage 
granules rich in P-selectin, the von Willebrand factor, and angiopoietin-2. P-selectin is 
involved in leukocyte adhesion, while the von Willebrand factor contributes to platelet 
adhesion and angiopoietin-2 modulates endothelial permeability (van Hinsberg 2012).  
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AIMS OF THE STUDY 
 
 
 
This thesis study aimed to investigate inflammatory and blood coagulation mechanisms 
during the immediate early reperfusion period of clinical renal transplantation. Due to the 
method of patient recruitment drawing from another interventional study, additional novel 
information concerning the intervention study pharmaceuticals was anticipated.    
 
 The specific aims of this research are as follows: 
 
I. To describe the early neutrophil activation and sequestration in clinical 
cadaveric renal transplantation and to explore the possible effects on 
clinical parameters and outcomes (study I). 
 
II. To describe the local and systemic response of the protein C–activated 
protein C axis in clinical renal transplantation (study II). 
 
III. To explore the activation of blood coagulation in the renal graft 
vasculature during early reperfusion and to investigate the possible 
clinical relevance (study III). 
 
IV.  To describe the systemic and renal graft local kinetics of matrix 
metalloproteinase 9 in clinical renal transplantation reperfusion and to 
explore the possible clinical implications (study IV).  
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PATIENTS AND METHODS 
 
PATIENTS AND STUDY DESIGN 
 
For this study, patients were recruited from a larger efficacy and safety study conducted 
within the Helsinki University Hospital Transplantation and Liver Surgery Clinic between 1999 
and 2001. Patients younger than 16 years, older than 65 years, with a malignant disease 
history, and with panel reactive antibodies (PRA) higher than 50% or who lost a previous graft 
within one year due to immunological reasons were excluded from the study. In addition, 
written informed consent was obtained before entering the study. A total of 168 patients 
were originally recruited, whereby 155 patients continued in the study and received a single 
9-mg/kg dose of antithymocyte globulin (ATG)-Fresenius (group A) or two 20-mg doses of 
basiliximab with a reduced dose of cyclosporin A (CsA) (group B) or a conventional CsA triple 
therapy without induction (group C) (Kyllönen et al. 2007). The local ethics committee of the 
surgical hospital at Helsinki University Hospital (HUH) approved the amendment to the study 
plan permitting additional blood sampling for this thesis project. A total of 45 patients 
participated in the additional analyses comprising the research in this thesis project, retaining 
the original randomization: group A (n = 15), group B (n = 16), and group C (n = 14). 
 
The administration of the different immunosuppressive agents was completed before 
commencing graft reperfusion. 
 
Laboratory analyses were conducted in the Department of Bacteriology and Immunology at 
Haartman Institute at the University of Helsinki (studies I, III, and IV), in the Department of 
Clinical Chemistry at HUCH and the Helsinki University Laboratory (HUSLAB) (studies I–IV), and 
in the Department of Molecular and Experimental Medicine, Scripps Research Institute (La 
Jolla, CA, USA) (study II). 
 
 
CLINICAL PATIENT DATA 
Donors 
 
All renal grafts were procured from brain-dead heart-beating donors. The donor age was 
recorded, and no differences existed between groups based on age. 
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Recipients 
 
Among recipients, age, gender, medication, etiology of the terminal uremia, weight, and 
height were recorded. 
 
RESEARCH SAMPLES 
Blood sampling and blood volume flowmetry 
 
For each patient, a preoperative and a pre-reperfusion blood sample was drawn from the 
central venous cannula. The preoperative sample was obtained after induction of anesthesia, 
but before commencing with the surgical procedure. The pre-reperfusion sample was 
obtained after the completion of vessel anastomoses, but before declamping of the iliac 
artery and proximal iliac vein. Paired local reperfusion blood samples were obtained at 1 and 
5 min after reperfusion from the graft supplying artery and vein (i.e., from the recipient’s iliac 
artery proximal to the anastomosis and from the renal vein of the graft, respectively). Samples 
were obtained via direct intraluminal needle aspiration by the operating and assisting 
surgeons. Along with the paired directly aspirated samples, the anesthesiologist also drew 
central venous samples. Finally, a 15-min post-reperfusion sample was drawn from the central 
venous cannula. Postoperative cubital vein blood samples were obtained at postoperative 
days 1, 2, 4, and 6. The volume of each blood sample was 10 ml, and samples were drawn into 
pyrogen-free plastic disposable syringes and immediately transferred to pyrogen-free test 
tubes. From these tubes, aliquots were further transferred into prechilled test tubes 
according to the particular laboratory method used (discussed below).  
 
Arterial blood flow was measured by the operating surgeon at 2- and 30-min post-reperfusion 
using a commercial ultrasound transit-time flowmeter (Cardiomed Volume Flowmeter, Medi-
Stim AS, Oslo, Norway). If the graft consisted of multiple arteries, all were measured and the 
sum was used for statistical analysis. The blood sampling and arterial blood flow 
measurement schema are summarized in Figure 6.  
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Figure 6.  
Schema for the blood sampling and flow measurements. 
 
 
 
LABORATORY METHODS 
Leukocyte counts (studies I and II) 
 
Leukocyte differential counts were obtained using a Technicon H2 hematology analyzer (Bayer 
Corporation, Tarrytown, NY, USA) operated by Helsinki University Clinic laboratory personnel. 
 
Adhesion molecules CD11b and L-selectin (studies I and II) 
 
Adhesion molecule CD11b and L-selectin (CD62L) expression on circulating neutrophils and 
monocytes were analyzed by means of flow cytometry. The corresponding cell labeling was 
carried out in a +0°C ice-water bath with ice-cold reagents. For each blood sample, a 1-ml 
aliquot was transferred into a prechilled polystyrene tube (Falcon No. 2058 Becton–Dickinson 
Labware, Lincoln Park, NJ, USA) supplemented with 1 ml of an ACD solution (pyrogen-free 
citrate, Baxter Healthcare, Norfolk, UK; Baxter product no. 93I08BH). The tube was kept in a 
styrofoam box containing 0°C water and ice until labeling. Sample preparation and cell double 
labeling were carried out as described elsewhere (Repo et al. 1993, Repo et al. 1995). Briefly, 
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for neutrophils, 25-μl aliquots of blood were labeled within 24 h of sampling with fluorescent 
anti-CD11b–phycoerythrin (PE) and anti-CD62L–fluorescein isothiocyanate (FITC) antibodies 
(BD Biosciences, San Jose, California, USA) and incubated in the dark at 4°C. Erythrocytes were 
lysed with FACS lysing solution (BENEX Limited, BD Biosciences, Shannon, Country Clare, 
Ireland) and leukocytes were collected by centrifugation at 4°C. Labeled cells were 
resuspended in 1% formalin and kept at 4°C until analysis. Similarly, for monocytes, two 25-μl 
aliquots were labeled with anti-CD11b-PE and anti-CD14-FITC or anti-CD62L-FITC and anti-
CD14-PE. Data acquisition and analysis were completed using a FACSort flow cytometer and 
CellQuest Pro analysis software (both from BD Biosciences, San Jose, California, USA). 
Neutrophils were identified by their light scattering pattern, while monocytes were identified 
by their light scattering pattern and CD14 positivity. Adhesion molecule expressions are 
reported in relative fluorescence units (RFUs)—that is, as the mean channel of the positive-
fluorescing cell population. 
 
Lactoferrin (study I) 
 
Lactoferrin was measured using enzyme-linked immunosorbent assay (ELISA) by anti-
lactoferrin antiserum (Dako, Glostrup, Denmark), purified in a lactoferrin-Sepharose 
(Amersham Pharmacia Biotech, Uppsala, Sweden) affinity column and labeled with alkaline 
phosphatase. Microtiter plates were coated with 5-μg/mL affinity-purified antibodies. Purified 
human lactoferrin (Sigma Chemical Co., St. Louis, MO, USA) was used as the standard, and the 
standards and samples were diluted to cover a range of 5 to 100 ng/mL.  
 
Protein C and activated protein C (study II) 
 
The plasma levels of protein C and APC were determined using an enzyme capture assay as 
previously described (Gruber & Griffin 1992). Briefly, a monoclonal antibody against protein C 
was immobilized on microplates, and the surface was blocked. Plasma samples supplemented 
with benzamidine, a reversible inhibitor of thrombin, APC, and trypsin-like proteases were 
incubated in the wells to capture APC and the protein C antigen. Then, the plates were 
washed to remove sample constituents and benzamidine. The amidolytic activity of the 
captured APC was measured using the chromogenic substrate S-2366 (Chromogenix AB, 
Mölndal, Sweden). Assays were run in duplicate, and a noncommercial plasma pool was used 
as the standard. The sensitivity of the assay was set to 5 pmol/L, corresponding to 13% of the 
normal mean plasma level of APC. 
 
Total protein C was measured by activating the bound protein C in the immunocaptured 
samples using a snake venom activator enzyme (Protac, American Diagnostica, Greenwich, 
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CN, USA), followed by measurement of the amidolytic activity on a chromogenic substrate S-
2366. Since APC was less than 1% of the total protein C, the amidolytic activity observed after 
Protac activation essentially equaled the total protein C level. Assays were run in duplicate, 
and pooled normal human plasma (Precision Biologicals, Dartmouth, Nova Scotia, Canada) 
was used as the standard. The results of APC and the total protein C are expressed as a 
percentage relative to the plasma pool defined as 100%. 
 
Coagulation parameters (study III) 
 
All coagulation parameters were assayed using commercial ELISA kits following the 
manufacturer’s instructions, including the following: prothrombin fragment F1+2 (Enzygnost 
F1.2micro, Dade Behring, Liederbach, Germany); tPA antigen and tPA activity (t-PA Actibind, 
Technoclone, Vienna, Austria); PAI-1 (PAI-1 Antigen ELISA, Technoclone, Vienna, Austria); and 
D-dimer (IMUCLONE D-Dimer ELISA, American Diagnostica, Stamford, CT, USA).  
 
MMP-9 and TIMP-1 (study IV) 
 
Extracellular protease and protease-inhibitor parameters were assayed using commercial 
ELISA kits following the manufacturer’s instructions (Biotrak, Amersham Pharmacia Biotech, 
Little Chalont, UK).  
 
 
 
STATISTICAL ANALYSIS 
 
Statistical analyses were carried out using various versions of SPSS software for Microsoft 
Windows (versions 9–20, SPSS Inc., Chicago, IL, USA). The non-parametric Wilcoxon test for 
paired samples was used to test the significance of the transrenal changes across parameters 
(studies I–IV). The Mann–Whitney U test (studies I–IV) and binary logistic regression (study I) 
were used for the analyses between groups. Multiple linear regression analysis was used to 
evaluate the relative importance of explanatory variables on the observed behavior of the 
variable of interest (study II). The Pearson product–moment correlation coefficient was 
determined to explore linear correlations between variables (studies I, II, and IV). The receiver 
operator characteristic (ROC) analysis was used to test the predictive value of parameters 
(study IV).  
 
54 
 
Since ATG administration resulted in quite marked changes for some of the parameters 
studied, excluding group A patients and/or a combination of group B and C patients as a larger 
combined BC group was done for some of the statistical analyses, as indicated in the original 
publications (studies I, III, and IV). Patient data are presented as medians and range. 
  
  
55 
 
RESULTS 
 
PATIENT AND CLINICAL OUTCOME DATA 
 
Cold and warm ischemia times did not differ between groups. The median cold ischemia times 
were as follows: group A, 24.0 h; group B, 24.8 h; and group C, 21.6 h. In comparison, the 
warm ischemia times were 0.74 h for group A, 0.65 h for group B, and 0.81 h for group C. 
Table 2 summarizes the characteristics for the clinical recipients. 
 
 Table 2. 
Patient data. 
 
Group A     B          C  
     
Age 51 (24-62) 44 (26-61) 54 (29-64)  
Sex (M/F)  10/5 6/10 8/6  
Diagnosis     
   Diabetic nephropathy  5 5 4  
   Polycystic renal disease  4 2 4  
   Chronic glomerulonephritis 2 2 0  
   IgA nephropathy 2 0 1  
   Chronic pyelonephritis 0 1 2  
   Other 2 6 3  
Adapted from Turunen AJ et al. Association of graft neutrophil sequestration with delayed graft function in 
clinical renal transplantation. Transplantation 2004; 77:1821-1826. Reprinted with permission from the copyright 
holder. 
 
 
One patient developed acute myocardial infarction during the postoperative phase and died 
with a well-functioning kidney graft on day 10 post-transplantation. One graft was lost on day 
69 post-transplantation, having regained only marginal functioning for a period of time 
following transplantation. Another graft was lost to the recurrence of focal segmental 
glomerulosclerosis on day 111 post-transplantation. One-year patient survival for the entire 
study population reached 97%, while graft survival was 93%. 
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Delayed graft function (DGF) 
 
The overall incidence of DGF irrespective of study group was 29% (Table 3). In patients not 
treated with ATG, DGF associated with a longer cold ischemia time (p = 0.036). 
 
Table 3. 
Delayed graft function and the 1st month creatinine values by study groups 
 
Group A     B          C  
     
Delayed graft function 3/15 5/16 5/14  
     
Serum creatinine (μmol/L)     
   6th post op. day  145 (68-597) 152 (70-634) 129 (83-1144)  
  21st post op day 130 (71-185) 109 (65-262) 121 (75-475)  
  30th post op day 130 (83-179) 124 (75-278) 121 (89-368)  
     
Adapted from Turunen AJ et al. Activated protein C reduces graft neutrophil activation in clinical renal 
transplantation. American Journal of Transplantation 2005; 5: 2204–2212. Reprinted with permission from the 
copyright holder. 
 
 
SYSTEMIC INFLAMMATION AND COAGULATION RESPONSES 
 
Patients receiving ATG (group A) 
 
A single-dose perioperative administration of ATG resulted in profound alterations in virtually 
all of the parameters studied unparalleled by other induction schemes. In addition to the 
expected lymphocyte ablative effect of ATG, the numbers of circulating neutrophils and 
monocytes also significantly diminished. Thus, by the time of renal graft vascular declamping, 
circulating neutrophil numbers decreased to 27% of the values observed at the induction of 
anesthesia. Simultaneously and illustrating the relative cell lineage specificity of ATG, 
however, the circulating lymphocyte counts were as low as 4%. 
 
Mirroring the cell depleting quality of ATG, a simultaneous increase in the phagocyte 
activation markers was observed, whereby the CD11b expression of neutrophils and 
monocytes roughly doubled. A concomitant twofold increase in systemic lactoferrin and up to 
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a tenfold increase in the MMP-9 concentration was also observed. Neutrophil L-selectin 
expression remained stable, however. 
  
Across all study groups, the PC and APC levels fell within normal (e.g., 100%) levels at the 
beginning of surgery. Upon ATG administration, however, systemic APC levels doubled, while 
the elevation continued when reperfusion of the graft began. Correspondingly, among ATG-
treated patients, systemic platelet counts decreased and F1+2, the tPA antigen, tPA activity, 
and the D-dimer levels increased significantly before reperfusion. In addition, D-dimer 
continued increasing following reperfusion. Table 4 summarizes the ATG effects.  
 
 
Table 4. 
ATG effects before surgery and reperfusion (*p<0.05 vs. Before operation). 
 
 
 
Patients not receiving ATG (groups B and C) 
 
Among patients not treated with ATG, only subtle changes in the phagocyte activation were 
observed in the systemic circulation. The systemic neutrophil CD11b expression decreased 
during the early stages of surgery, but remained stable after declamping of the graft vessels. 
The systemic neutrophil L-selectin expression mirrored changes to CD11b; as such, it 
increased before vascular declamping and remained stable thereafter (Table 5). The systemic 
lactoferrin concentration decreased slightly before reperfusion, but remained stable 
 Before Operation Before Reperfusion 
Neutrophil count (^10E9) 3.15 (1.30–7.26) 0.85 (0.27–1.25)* 
Monocyte count (^10E9) 0.48 (0.24–0.70) 0.03 (0.00–0.06)* 
Lymphocyte count (^10E9) 1.49 (1.09–3.34) 0.07 (0.04–0.35)* 
Platelet count 214 (109–374) 145 (71–283)* 
Neutrophil Cd11b (RFU) 261 (113–379) 407 (180–688)* 
Neutrophil L-selectin (RFU) 213 (109–272) 269 (172–310)* 
Lactoferrin (μg/l) 92 (44–197) 195 (91–461)* 
MMP-9 (ng/ml) 21 (7–43) 128 (76–286)* 
TIMP-1 (ng/ml) 161 (90–299) 142 (94–197)* 
APC (%) 119 (88–144) 232 (85–1246)* 
F1+2 1.2 (0.4–2.8) 1.8 (0.4–3.4)* 
tPA antigen 9 (1–25) 90 (29–138)* 
D-dimer 281 (8–678) 624 (27–4278)* 
58 
 
thereafter. By contrast, the MMP-9 systemic concentration increased slightly before 
reperfusion and, then, remained stable (Table 5). TIMP-1 systemic concentration remained 
constant. 
 
Neither the platelet count nor the prothrombin fragment F1+2 concentration exhibited any 
changes during the sampling time points. Prior to reperfusion, a modest yet statistically 
significant increase in the tPA antigen was observed, whereas the values during reperfusion 
remained stable. The systemic tPA activity variation ranged from 0 to 4 activity units/mL. 
However, 63% of patient systemic samples exhibited less tPA activity than the method 
detection threshold. The PAI-1 levels increased significantly before reperfusion and continued 
to increase during reperfusion, whereas an increase in D-dimer was observed only after 
commencing reperfusion.  
 
 
Table 5. 
Systemic and transrenal phagocyte activation markers  in patients without ATG induction. (* p<0.05 vs. 
Pre-operative values) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pre-operative Pre-reperfusion 1-min (artery) 5-min (artery) 
CD11b (RFU) 242 (127–524) 224 (102–958)* 224 (116–451) 206 (98–650) 
L-selectin (RFU) 203 (75–372) 250 (104–394)* 235 (100–412) 230 (109–417) 
Lactoferrin (μg/l) 142 (46–260) 130 (55–237)* 118 (41–210) 124 (42–218) 
MMP-9 (ng/ml) 23 (6–48) 31 (15–93)* 28 (14–53) 31 (15-193) 
TIMP-1 (ng/ml) 157 (90–299) 148 (100–291) 144 (49–273) 151 (87–302) 
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The systemic blood protein C content exhibited only minor changes during surgery. This was 
also observed for APC. For both, a more marked increase was observed during the first 
postoperative week (Figure 7). 
 
 
Figure 7.  
Protein C and activated protein C (APC) during surgery and the first post-operative week. 
 
Adapted from Turunen AJ et al. Activated protein C reduces graft neutrophil activation in clinical renal 
transplantation. American Journal of Transplantation 2005; 5: 2204–2212. Reprinted with permission from the 
copyright holder. 
 
 
INFLAMMATION IN THE RENAL GRAFT VASCULAR BED DURING REPERFUSION 
 
To simplify the presentation of findings in the following section, we refer to the two blood 
sampling time points after declamping of the renal graft vessels as “1 min” and “5 min”. The 
Greek letter Δ represents the transrenal difference in a parameter calculated by subtracting 
the arterial value from the venous value. Positive values, therefore, indicate graft venous 
efflux and negative values indicate graft parenchymal or vascular endothelial sequestration. 
Median values are reported here; the respective ranges of values appear in the original 
publications in the appendix. 
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Patients not receiving ATG (groups B and C) 
 
At 1 min, the transrenal cell counts for neutrophils and lymphocytes remained unchanged, 
while a modest but statistically significant venous efflux of monocytes was observed (Δ = 0.02 
x 109cells/l, p = 0.04, Figure 8). Neutrophil CD11b and L-selectin expressions exhibited no 
transrenal changes and MMP-9 also remained unchanged. Yet, a lactoferrin venous efflux was 
detected (Δ = 15μg/l, p = 0.012). Although transrenal changes to either the neutrophil L-
selectin expression or neutrophil count as such were not observed, a significant correlation 
between the two emerged [Δ(L-selectin) vs. Δ(neutrophil count), R = 0.494, p = 0.012]. In 
addition, the transrenal MMP-9 difference inversely correlated with a concomitant transrenal 
neutrophil difference (R = 0.424, p = 0.027), indicating that a strong renal sequestration of 
neutrophils was associated with a strong renal release of MMP-9. At 2 min, poor graft blood 
flow associated with a strong neutrophil sequestration at 1 min (R = 0.51, p = 0.007). 
 
At 5 min, a marked neutrophil sequestration (Δ = –0.17 x 109cells/l, p < 0.001) in the renal 
graft was observed (Figure 8). In comparison, only a modest yet still statistically significant 
sequestration of the lymphocytes (Δ = –0.04 x 109cells/l, p = 0.009) and monocytes (Δ = –0.03 
x 109cells/l, p = 0.001) was observed. Neutrophil CD11b and L-selectin expressions remained 
without transrenal changes. Furthermore, no significant transrenal changes were detected for 
lactoferrin or MMP-9. The graft blood flow at 30 min correlated with neutrophil sequestration 
at 5 min (R = 0.53, p = 0.005, Figure 9).  
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Figure 8.  
Reperfusion-induced transrenal difference (Δ) of neutrophil (gray bars), lymphocyte (hatched 
bars) and monocyte (white bars) counts at 1 and 5 min after reperfusion, Δ < 0 implying cell 
sequestration in the kidney graft. *p<0.05; **p<0.001.  
 
 
Adapted from Turunen AJ et al. Association of graft neutrophil sequestration with delayed graft function in 
clinical renal transplantation. Transplantation 2004; 12:1821 Reprinted with permission from the copyright 
holder.  
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Figure 9.  
Graft blood flow correlation to neutrophil sequestration.  
 
 
Adapted from from Turunen AJ et al. Association of graft neutrophil sequestration with delayed graft function in 
clinical renal transplantation. Transplantation 2004; 12:1821 Reprinted with permission from the copyright 
holder. 
 
 
The emergence of DGF was associated with a higher sequestration of lymphocytes, 
monocytes, and neutrophils at 5 min. To further investigate the relative importance of 
different leukocyte populations, a binary logistic regression analysis was carried out, where 
graft neutrophil sequestration emerged as the most important predictor (p < 0.001). The 
association between DGF and MMP-9 appeared moderately significant (p = 0.05).  
 
 
Patients receiving ATG (group A) 
 
Due to the profound systemic leukocyte depletion, the transrenal differences in neutrophil, 
lymphocyte, or monocyte counts were not evaluated. Similarly, no transrenal differences 
were found for lactoferrin, MMP-9, or TIMP-1. 
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COAGULATION IN RENAL GRAFT VASCULAR BED DURING REPERFUSION 
 
Patients not receiving ATG (groups B and C) 
 
At 1 min, significant effluxes from the graft vein were observed for the tPA antigen (Δ = 14 
ng/ml, p < 0.001) and D-dimer (Δ = 58 ng/ml, p = 0.001). A transrenal increase in the tPA 
activity was also noted (Δ = 0.5 activity units/ml, p = 0.002). Yet, the platelet count, PAI-1, 
F1+2, PC, and APC exhibited no changes. 
 
At 5 min, a significant efflux was detected only for the tPa antigen (Δ = 5 ng/ml, p < 0.001), 
while no transrenal change to the tPa activity was detected. In addition, no significant 
transrenal changes could be detected for the platelet count, PC, APC, F1+2, or D-dimer. Yet, a 
significant uptake to PAI-1 was observed (Δ = –3 ng/ml, p = 0.014). 
 
Patients receiving ATG (group A) 
 
Similar to patients with no ATG exposure, a significant positive venous efflux for tPA antigen 
at 1 min (Δ = 9 ng/ml) and 5 min (Δ = 5 ng/ml) as well as an efflux for D-dimer at 1 min (Δ = 71 
ng/ml) was observed. Contrary to patients with no ATG exposure, a significant PAI-1 venous 
efflux was observed both at 1 min (Δ = 5 ng/ml) and 5 min (Δ = 3 ng/ml). No transrenal 
differences, however, were found for the platelet count, F1+2, or the tPa activity. 
 
INTERACTION OF COAGULATION AND INFLAMMATION IN THE RENAL GRAFT 
VASCULAR BED DURING REPERFUSION 
 
Patients receiving ATG (group A) 
 
The APC transrenal difference at 1 min correlated directly with the neutrophil L-selectin 
expression transrenal differences at 1 min (R = 0.7, p = 0.01) and 5 min (R = 0.6, p = 0.02). Yet, 
the APC transrenal difference at 1 min correlated inversely with the lactoferrin difference at 5 
min (R = 0.6, p = 0.02). An inverse correlation was also found between the transrenal APC 
difference at 5 min and the concomitant neutrophil CD11b expression difference (R = –0.8, p = 
0.001, Figure 10).  
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Figure 10.  
Correlations of the transrenal differences for APC with the transrenal differences for the neutrophil 
activation markers in group A. 
 
 
 
Adapted from Turunen AJ et al. Activated protein C reduces graft neutrophil activation in clinical renal 
transplantation. Am J Transplant. 2005; 5:2204.Reprinted with permission from the copyright holder. 
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DISCUSSION  
 
INFLAMMATION WITHIN THE GRAFT VASCULAR BED (STUDIES I AND IV) 
 
Neutrophil degranulation provides us with a trail of information that can be used to measure 
the established soluble products of neutrophil activation. In this project, a significant 
lactoferrin venous efflux was detected early at 1 min after vascular declamping (study I). At 5 
min, this finding was mirrored by the significant further sequestration of neutrophils in the 
renal graft. At this point, we estimate that about 4% of the circulating neutrophils was cleared 
by the renal graft. The relevance of this cell clearance is highlighted by the fact that the 
increased neutrophil sequestration correlated with a diminished graft blood flow at 30 min 
after vascular declamping (study I). While other leukocyte populations were also sequestered 
at 5 min, an association with the blood flow was only found for neutrophil sequestration. This 
appears to be in line with a classic experimental finding regarding leukocyte capillary plugging 
causing a regional no-reflow phenomenon (Engler et al. 1983). Importantly, DGF also 
associated with this neutrophil sequestration (study I). 
 
As another product of neutrophil degranulation, MMP-9 is also indicative of neutrophil 
activation. Significant MMP-9 transrenal changes were absent across all patient groups. Yet, 
the immense systemic ATG-related elevation of systemically circulating MMP-9 largely 
obscured the analysis of the renal graft MMP-9 production among group A patients (study IV). 
However, within group BC, grafts cold-stored for longer periods displayed a venous release of 
MMP-9. In addition, a strong renal neutrophil sequestration correlated with a strong renal 
release of MMP-9, suggesting that this MMP-9 release indeed results from trapped neutrophil 
sources (study IV). Other possible sites of release exist, however, including, for instance, 
activated glomerular endothelial cells and tubular cells (Basile et al. 2004). In this thesis study, 
an association between MMP-9 release and the emergence of DGF was found (study IV). 
Damage due to renal ischemic insult has been associated with MMP-9 in experimental 
settings. Furthermore, in a rat model, ischemia-related microvascular disturbances could be 
reversed with tetracycline antibiotic, which inhibit MMPs (Sutton et al. 2005).  
 
The molecular sequence of the neutrophil recruitment process has been relatively well 
outlined previously (Ley 1996, McEver et al. 1995). Thus, members from both the selectin and 
integrin families of adhesion molecules were investigated to further elucidate the 
mechanisms of the neutrophil-associated pathophysiology. After successfully demonstrating 
the graft neutrophil sequestration, the corresponding results for the adhesion molecules were 
somewhat surprising, since no statistically significant arteriovenous differences in the 
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adhesion molecule expressions were detected (study I). However, several factors might 
contribute to the lack of differences: 
 
Firstly, as L-selectin sheds from the neutrophil surface upon committing to integrin-mediated 
adhesion, the sampled population of neutrophils may contain both additional activated (low 
L-selectin, high CD11b) and fewer activated (high L-selectin, low CD11b) cells. Should this be 
the case, the subpopulations would cancel each other out since the flow cytometric 
determination of expression actually represents the median expression of any particular 
neutrophil cohort (Repo et al. 1993). 
 
Secondly, it remains unknown to what degree a “touch-and-go” type of activation is possible 
when blood traverses the capillary vascular beds. It is plausible that the vast majority of 
activated cells are immediately recruited during the first pass, whereby very little of this 
population remains available for sampling on the venous side. In this study, L-selectin at 1 min 
correlated with neutrophil sequestration, providing some indirect support for this reasoning 
(study I). 
 
Thirdly, numerous means of alternative cell trapping may occur, more or less irrespective of 
the cell activation status. Experimentally, a low shear stress acts as an autonomous trigger of 
cell adhesion (Ploppa et al. 2012). In addition, the same experiment highlighted various roles 
for the leukocyte subpopulations in adhesion, since the monocyte presence led to a significant 
increase in neutrophil adhesion without a notable neutrophil activation. Furthermore, 
ischemic capillary endothelial cell swelling or sloughing might disturb the flow and affect 
shear stress, thus increasing neutrophil adhesion.  
 
All of the abovementioned phenomena serve to confound the assays focused on adhesion 
molecules. In hindsight, measuring the venous efflux of soluble L-selectin during reperfusion 
would have strengthened the research protocol, an additional consideration that was 
subsequently examined. After publishing study I, a subsequent analysis among 19 patients (5 
in group A, 14 in group BC) examined whether soluble L-selectin is elevated in the graft 
venous blood. This appeared to indeed be the case among 14 patients not receiving ATG. At 1 
min, a statistically significant efflux was present, while at 5 min a similar trend emerged, 
although it did not reach statistical significance (data not shown). 
 
 
 
 
 
 
  
67 
 
COAGULATION WITHIN THE GRAFT VASCULAR BED (STUDY III) 
 
Being closely tied to the inflammatory response, unwanted blood coagulation activity 
threatens graft viability. The heightened incidence of DGF and early graft loss during the first 
six months post-transplantation was established for an antiphospholipid syndrome–
associated prothrombotic state (Morales et al. 2017). Many other potential risk factors for 
thrombosis have been recognized, although established screening or preventive protocols 
remain lacking (Andrassy et al. 2004, Parajuli et al. 2016). 
 
Here, both groups A and BC exhibited a significant venous release of the tPA antigen from the 
graft during early reperfusion (study III). However, during this time, tPA activity in the graft 
artery and vein remained static. It is likely that tPA activity is held in check by PAI-1, which is 
simultaneously sequestered in the graft among group A patients (study III). As a result, the net 
effect inside the renal vasculature results from antifibrinolysis during early reperfusion. 
A particularly intriguing finding stems from the tPA-antigen release being complemented by 
the efflux of D-dimer rather than the efflux of prothrombin fragment F1+2. The absence of 
F1+2 release indicates that no thrombin formation takes place inside the renal vasculature 
during cold storage or reperfusion. Together, these markers are, thus, indicative of preformed 
fibrin lysis rather than the ongoing deposition and lysis of fibrin during early reperfusion 
(study III).  
 
When, then, did the fibrin deposition and subsequent fibrinolysis take place? The D-dimer 
venous efflux is significant at 1 min, but not at 5 min. This finding is consistent with washout 
type kinetics and, as such, might point to the period of cold storage. It is plausible that renal 
microthrombi form during the intensive care period for the donor. If flushing the graft with 
preservation solution is unable to clear these clots, fibrinolysis might slowly propagate during 
the many hours of cold storage. A D-dimer washout is then observed once blood flow is re-
established.  
 
Similar behavior among coagulation markers was observed in the systemic samples of brain-
dead organ donors (Lisman et al. 2011). To our knowledge, our findings here, however, 
provide one of the most direct pieces of evidence regarding intravascular coagulation and the 
fibrinolysis of reperfused renal grafts in humans. In the present study, we did not control for 
pre-existing prothrombotic states, although an independent role for the venous efflux of 
coagulation markers emerged through a multivariate analysis of DGF risk factors (study III). 
Contradictory results concerning DGF and microthrombi appear in the literature. In a series of 
pretransplant donor biopsies, no association was found between donor glomerular 
microthrombi and DGF (Sood et al. 2015). However, Sood et al. argued that in their series 
even grafts with the most widespread glomerular microthrombi represented relatively mild 
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involvement. Thus, in the histological sections, only 8% of the glomeruli demonstrated more 
than 50% capillary loop occlusion.   
 
ATG EFFECTS AND SUBSEQUENT APC RENAL UPTAKE (STUDY II) 
 
Most important, this study was designed to study phenomena occurring in the local vascular 
bed of the renal graft. Thus, the vigorous systemic effects of ATG were largely detrimental. 
However, an unexpected research opportunity presented itself as novel data concerning the 
systemic and local effects of ATG could be collected. Given the measured transrenal 
parameters, patients receiving ATG differed from other patients most notably in relation to 
APC sequestration. At 1 min after vascular declamping, systemic circulating APC levels had 
tripled compared with presurgical values. Thus, with a heightened systemic availability, the 
avid sequestration of APC was observed, whereby 20% uptake by the graft occurred. 
Importantly, this sequestration correlated with the transrenal markers of neutrophil 
activation such that an increasing neutrophil activation associated with greater APC uptake. 
Consumption by the graft endothelium activated or injured via ischemic preservation may 
offer one explanation, which agrees with previous experimental and clinical results 
concerning APC (Lattenist et al. 2016, Petäjä et al. 2001). The cellular mechanisms possibly 
behind APC sequestration include ischemia-induced increased thrombomodulin expression on 
the endothelial cells (Faust et al. 2001). Many other modulatory pathways for the renal 
protective effects of APC have also been suggested, such as cytokine-signaling blockade, cell 
adhesion control, leukocyte migration, and cell apoptosis (Gupta et al. 2009). More recent 
research found that APC may also stabilize endothelial barriers preventing vascular leakage 
(Griffin et al. 2015). Thus, we may also postulate that the previously observed avid 
sequestration of APC partially results from capillary leakage into the parenchyma. This leakage 
then subsequently diminishes when the endothelial barrier functionality is restored by APC, so 
that at 5 min after declamping it is no longer detected. Regardless of the underlying 
mechanism, our findings may well represent the most concrete in vivo evidence for the anti-
inflammatory efficacy of APC in humans. 
 
 
DELAYED GRAFT FUNCTION (DGF) 
 
At the heart of DGF etiology lies the complex pathophysiology of renal I/R injury (Siedlecki et 
al. 2011, Jang & Rabb 2009). In rodent models, some protective effects have been observed 
among interventions targeting various leukocyte adhesion molecules (Fuller et al. 2001). In 
humans, an early study utilizing a blocking antibody against intercellular adhesion molecule 1 
(ICAM-1) protected against renal ischemic injury (Haug et al. 1993), although a randomized 
prospective study failed to show its efficacy in DGF (Salmela et al. 1999). In general, only 
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limited clinical success largely outside the field of transplantation has been observed 
(Yonekawa & Harlan 2005). 
 
In this thesis, we found unique evidence for rapid inflammatory activation within the graft 
associated with subsequent DGF (study I). The magnitude of graft neutrophil sequestration 
was fourfold that of lymphocytes, in turn indicative of the active mechanisms behind 
neutrophil sequestration (studies I and IV). From a comparison of pre- and postreperfusion 
biopsies, histological evidence has linked glomerular neutrophil infiltration to the 
development of DGF (Koo et al. 1998). 
 
In addition, it is unsurprising that the coagulation parameter findings also associated with the 
resulting DGF. Here, we demonstrated that a high efflux of D-dimer and the efflux of tPA-
antigens associated with emerging DGF (study III). Some data do exist concerning the possible 
direct pro-inflammatory effects of fibrin degradation products (Jennewein et al. 2011), but 
clinical intervention trials in particular presented contradictory results (Jennewein et al. 2011). 
Thus, it is more tempting to interpret the aforementioned associations to be more of implicit 
quality. Hence, tPA antigen efflux serves as an index parameter for the endothelial injury 
severity and D-dimer as an index parameter for microthrombi dissolution. While endothelial 
injury results from brain damage injury as well as cold preservation, our D-dimer results 
importantly suggest that graft fibrin deposition occurs before organ procurement. 
 
 
STUDY DESIGN 
 
One of the main challenges to this study stems from the sample size. Once committing to the 
study, the basic setup of performing a “daughter study” using patients from a larger 
randomized study seemed advantageous. Thus, we circumvented some of the bureaucracy 
relating to setting up a clinical study and shared personnel already appointed for the larger 
study. We estimated that 45 patients would be sufficient to test the underlying hypotheses 
regarding neutrophil activation and to demonstrate the corresponding adhesion molecule and 
other laboratory marker changes. This estimate was based only on expert opinion without 
performing formal power calculations. Early on, it became clear, however, that group A 
patients’ immunosuppression resulted in early systemic inflammatory behavior quite different 
to the other two groups and consistent with cytokine release syndrome (Kyllönen et al. 2007). 
While this proved interesting in its own right, this dissimilarity raised immediate concerns 
regarding the statistical power of detecting more subtle yet important inflammatory marker 
changes. These concerns proved valid, since we had to combine groups B and C for many 
analyses in order to meaningfully interpret the results. In many ways, these two groups are 
similar, although the fundamental disparity in immunosuppression remains. However, we feel 
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that the likely consequences then would introduce additional confounding factors, thus 
diminishing the statistical power rather than creating false-positive results.  
 
However, while problematic as described, the ATG-induced systemic inflammatory reaction 
also allowed for an unexpected research opportunity through an investigation of the 
extraordinary concentrations of APC in conventionally cold-stored kidney graft vascular beds. 
This opportunity was fruitfully exploited to produce novel data.  
 
Another study design challenge relates to the differential coefficient nature of the 
measurements made from the blood samples aspirated locally from the graft vessels. 
Evaluating the transrenal changes this way, yields freeze-frame information only of a highly 
dynamic underlying process. Tapping to graft vessels using a cannulation system for several 
minutes during reperfusion would have provided more integrated results, but was not 
technically possible at the time. Thus, the integrated magnitude of a particular biomarker 
sequestration or its release remains open to speculation. 
 
By contrast, compared to obtaining pre- and postreperfusion biopsies, local arterial and 
venous blood samples likely represent a considerable step forward in our ability to detect 
rapid changes. In our study, we found that already during the first minutes of reperfusion 
considerable fluctuations occur in many marker values. We would not expect that a biopsy-
based protocol would reveal the early changes in the APC, tPA, or D-dimer values reported 
here. However, as discussed above, they can be logically explained and, taken with the data 
on neutrophil sequestration, represent the most insightful pieces of novel information found 
through this study. 
 
 
FUTURE PROSPECTS 
 
Clinically, the most noteworthy findings from this study lie in the associations with emerging 
DGF. As the transplantation community worldwide turns towards ever more compromised 
organ sources, countering DGF and its consequences remain crucial objectives (Summers et al. 
2015, Heilman et al. 2015). If donors following cardiac death are utilized, the risk of the graft 
recipient experiencing DGF doubles (Summers et al. 2015). ECD kidneys display a similar 
inferiority, albeit to a lesser degree. At our institution, the proportion of UNOS extended 
criteria donors rose from an initial 2.9% during the 1980s to reach 26.3% by 2007 reflecting a 
global trend (Salmela & Kyllönen 2007). 
 
Based on the current literature and the findings presented here, we feel somewhat strongly 
that the tremendous redundancy in the innate immune activation pathways and effector 
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functions are likely to prohibit any decisive pharmacological breakthrough in the treatment of 
renal I/R injury in the near future. Most likely, the most expedient means of improving the 
prognosis for deceased donor kidneys lies in concerted national efforts aimed at improving 
deceased donor intensive care. Regrettably, such efforts will not help when non-heart-beating 
donors are considered. It is highly likely that in the near future these new donor pools will also 
require consideration in Finland. Thus, further research in this challenging field is very much 
warranted. With these new donor pools, at the very least, the tedious task of further 
curtailing the cold preservation time may be possible (Peeters & Vanholder 2008). In addition, 
reconditioning the injured kidney graft with normothermic ex vivo perfusion has emerged as 
an exciting prospect. This approach eloquently bypasses the abovementioned problem of 
inflammatory redundancy. Instead, a “closed environment” allows the injured graft to regain 
metabolic activity supported by red cell–based oxygenated perfusate containing no 
inflammatory cells or soluble mediators (Hosgood et al. 2017).  
 
The most appealing future pharmacological intervention might be therapy relying on APC or 
some other agent with anticoagulation properties. The previous clinical use of APC to treat 
sepsis was also established as pharmacologically safe in solid organ transplantation setting  
(Funk et al. 2011), thus paving the way for expanding use. Graft vasculature flush treatment, 
donor pretreatment, or preservation solution supplementation, all represent treatment 
modalities worth consideration.  
 
In addition, better predicting grafts suffering from DGF would carry immediate clinical value 
since protective measures could be undertaken to aid jeopardized grafts. Promising predictive 
techniques have been described, but require refinement for clinical use (Hattori et al. 2005, 
Schmitz et al. 2008). Readily available interventions for selected recipients could include the 
avoidance of nephrotoxic immunosuppressants and timely arrangements for supportive 
hemodialysis.    
 
Finally, national attitudes towards living donation should be examined, and healthcare 
practices and policies revised accordingly. Norway undertook a quite different path from 
Finland, whereby living donation has become common. As minimally invasive surgical 
donation techniques evolve, short-term ailments for donors considerably diminish. Yet, 
thorough donor precounseling is mandatory, since minor but real long-term risks remain 
(Steiner 2016). For recipients, the long-term graft prognosis for this type of donation is 
excellent. 
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CONCLUSIONS 
 
 
 
I. Our results indicate that neutrophil activation during human renal graft 
reperfusion is a very rapid phenomenon. Significantly elevated lactoferrin 
concentration is detected in graft venous blood immediately after vascular 
declamping. Graft artery and venous blood sampling repeated after five minutes 
reveals significant ongoing neutrophil sequestration in the graft. This sequestration 
is associated with diminishing graft arterial blood flow. The patients later 
diagnosed with DGF have significantly higher renal graft neutrophil sequestration.  
 
II. Among its’ other effects, high dose peroperative ATG administration causes very 
marked rise of circulating APC. During reperfusion, avid renal graft uptake of APC is 
observed. APC uptake is associated with renal neutrophil activation and may 
reflect APC protective role as an endogenous anti-inflammatory mediator. 
 
III. Results on blood coagulation markers suggest that renal grafts from deceased 
donors have intravascular fibrin deposits that continue to be degraded during cold 
preservation. Marked d-dimer venous release during reperfusion is associated with 
ensuing DGF. These findings imply that future research efforts may be directed 
towards donor care interventions that take place before organ procurement. 
 
IV. Surgery itself does not affect MMP9 circulating levels, whereas ATG administration 
results in very robust systemic rise. While no graft sequestration or release of 
MMP9 occurs uniformly, the grafts that do display MMP9 wash-out are cold stored 
for longer periods and are predisposed to develop DGF. A larger focused study is 
needed to evaluate, whether MMP9 has a unique pathophysiological role or is 
mere an implicit marker of inflammatory injury. 
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